Are you the publisher? Claim or contact us about this channel

Embed this content in your HTML


Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog

Channel Description:

Biotechnology Forums -

older | 1 | .... | 33 | 34 | (Page 35) | 36 | 37 | .... | 119 | newer

    0 0

    Seattle Genetics is an American biotechnology firm that develops antibiotic drug regimes for treating cancer. This company develops ADCs – antibody drug conjugates that are formulated for targeting and killing cancer cells. This class of drugs cause no harm to the neighboring normal and healthy cells thereby reducing the side effects caused by traditional chemotherapy drugs.

    Seattle genetics laid its foundation in the year 1998 and has its headquarters in Bothell, Washington. The company completed its first public offering in the year 2011 and is also a member of the NASDAQ. Till date, this company has over 550 employees and all are driven with passion for helping people who are suffering from cancer. They also strive hard and leave no stone unturned in reaching out to the masses where medical facilities are few and limited.

    Popular biotech products
    Seattle genetics developed ADCETRIS (brentuximab vedotin) which is meant for intravenous use only. This medication is meant for patients with relapsed Hodgkin lymphoma and systematic anaplastic large cell lymphoma. This drug received approval from FDA in the year 2011 and is the first in new class of ADCs (antibody - drug conjugates).
    ADCETRIS contains anti-CD30 monoclonal antibody that has cell – killing agent like properties – properties that have been developed by Seattle genetics ADC technology. This drug has participated in more than 20 ongoing clinical trials and 4 phase III studies. The trials are designed to test the efficacy of this drug in treating the early signs of lymphoma as well as certain additional types of CD-30 positive malignancies that includes cutaneous T-cell lymphoma (CTCL), B-cell lymphomas and mature T-cell lymphomas (MTCL).

    ADCEETRIS is approved in over 30 countries for treatment of relapsed Hodgkin lymphoma. These countries include United States, Canada, European Union and Switzerland. It is this one drug belonging to the class of ADCs that has been in use for more than 30 years in the United States for treating Hodgkin Lymphoma. Seattle genetics has joined hands with Millennium for jointly developing ADCETRIS.

    Latest discoveries
    Almost all the latest discoveries of Seattle genetics belong to the class of ADCs and are targeted towards treating several types of cancers. All the drugs have passed the phase I of clinical trials and the company will soon begin their testing of phase II followed by phase III after which they will be sent to FDA for approval. The following is a list of latest discoveries by Seattle genetics:
    • SGN – 75 for treating Renal cell carcinoma and everolimus.
    • ASG – 22ME targeted towards treating solid tumors.
    • SGN – CD19A meant for treating acute lymphoblastic leukemia and non – Hodgkin lymphoma.
    • SGN – CD33A developed for treating acute myeloid leukemia.
    • ASG – 15ME for treating bladder cancer.
    • SGN – LIV1A developed for treating breast cancer.
    All these are antibody – drug conjugates and are designed to specifically target the cancer cells while leaving the healthy cells untouched.

    Recent company takeovers
    Seattle genetics is expanding its business by collaborating with various firms for the ADC technology. The collaborating firms include AbbVie, Agensys, Bayer, Celldex, Daiichi Sankyo, Genentech, GlaxoSmithkline, Millennium, Pfizer and Progenics. Seattle genetics may also join hands with Genmab for expanding its area of research for the ADC class of drugs.

    Recent corporate news
    Seattle genetics is symbolized as SGEN in the NASDAQ stock. The price of stock of this firm is about $41.08.

    In the year 2012, the European Commission, granted conditional marketing authorization for ADCETRIS to Millennium. Health Canada also approved the drug but with conditions in the year 2013.

    Seattle genetics have benefitted a lot from the various collaborations for the ADC technology. Till date the firm has generated more than $225 million from the multiple licensing agreements and is expected to get an additional amount of $3.5 billion as potential milestones and royalties. In addition to this, there are more than 10 collaborator ADC programs in clinical development.

    Work culture
    Seattle genetics believes in making a positive impact in the lives of people struggling to outlive cancer. Individuals working with this firm are energetic, vibrant and can go to any extent to develop excellent ADC drugs for beating cancer to life. The employees of Seattle genetics work in collaboration to understand the values and goals of the organization and transform the ideas into targeted action. The firm appreciates and recognizes hard work and rewards its employees. It provides compensation and also has a benefit package that covers stock options, dental, medical, and disability insurance. The firm also has employee stock purchase plan and a 401 (K) plan for its employees. Seattle genetics rewards its employees for bringing laurels to the company by developing breakthrough technology for treating and beating a disease like cancer.

    Interesting events
    Any event in Seattle genetics is interesting with the regular innovations and developments they are coming up towards the treatment of cancer. The year 2013 has indeed been an eventful year for this firm. This year has witnessed the initiation of several clinical trials for some of the company’s new drugs.

    Several drugs developed by this firm have entered into the second phase of clinical trials but are yet to receive approval from the FDA. Seattle genetics in collaboration with millennium has entered into the Phase III clinical trial for ADCETRIS CD-30. This drug is formulated for its action against mature T-cell lymphoma.

    In the same year, the firm announced the initiation of two phases I trials for SGN-CD19A. The reports of all the trials are simultaneously presented in conferences to keep the world informed about the research data. The company also presented its reports on the second quarter of 2013 financial results.

    Recent job openings
    Seattle genetics is forever on the hunt for dynamic and highly qualified individuals to join their firm. The firm provides its employees with the appropriate resources to succeed and excel in their respective fields. Individuals who wish to build their future and career at Seattle genetics can drop in their resume and go through the recruitment process. The firm also has a reserved place for individuals with disabilities and they too can get in touch with the human resources department for the recruitment process.

    0 0

    ARIAD pharmaceuticals is a global oncology firm that laid its foundation in the year 1991 at the hands of Larry Bock, David Blech and Harvey Berger. This firm is solely based on researching and developing drugs for treating cancer. The types of cancer that form the core areas of research for developing new medicines include acute and chronic leukemia, lung cancer and other forms of difficult – to – treat cancer.
    ARIAD pharmaceuticals has its headquarters in Cambridge, Massachusetts and Luasanne. This pharmaceutical firm develops small molecular drugs that are effective for treating even the most difficult forms of cancers. The drugs are developed using structural and computational methodologies.

    ARIAD pharmaceutical is a member of NASDAQ and is symbolized as ARIA.

    Popular biotech products
    Inclusig is a drug developed by ARIAD pharmaceuticals for treatment of leukemia. This medication is indicated in patients suffering from chronic, accelerated or blast – phase myeloid leukemia (CML). Patients who are put on Inlcusig must have exhibited intolerance or resistance to prior tyrosine kinase inhibitor (TKI). Individuals who did not show a positive response to tyrosine kinase inhibitor are given Inclusig drugs. However, so far no clinical trials have confirmed the positive aspects of Inclusig in patients with leukemia. Inclusig also did not confirm any improvement in the clinical signs and symptoms of leukemia and neither did it increase the survival rate of patients.

    Latest discoveries
    ARIAD pharmaceutical is expanding its areas of research for testing the efficacy of two drugs namely Inclusig and AP26113 in treatment of various types of cancer. So far, the drug Inclusig has received approval from FDA for treatment of chronic myeloid leukemia and Ph + ALL.
    The Inclusig drug has been reported to give rise to several side effects. Clinical trials have reported that patients treated with Inclusig drug have suffered from arterial thrombosis, peripheral vascular thrombosis, myocardial infarction, stroke and cerebrovascular thrombosis. In addition to these cardiovascular diseases, Inclusig was also found to be the causative agent for liver toxicity, liver failure and death in patients. It has therefore been advised to constantly monitor the cardiac and liver functioning of patients treated with Inclusig. Deterioration in the functioning of these organs calls for immediate action which can also cause stoppage of Inclusig drug.

    The drug AP26113 is a unique drug discovered by the firm and has certain unique genetic features that have targeted action against cancer cells. This is a small molecule drug that has been formulated for killing tumor cells of non-small cell lung cancer. ROS1 is molecular target agent found in non-small cell lung cancer; the drug AP26113 has shown to be effective against ROS1. However several clinical trials are required to further validate the effectiveness of this drug against ROS1.

    Recent corporate news
    During the year 2013, the net recorded sales of inclusig were $13.9 million by the quarter end. An increase in the cash equivalents and marketable securities was raised from $351.9 million to $398.3 million. It has been estimated that by the end of this year, the cash equivalents and marketable securities will range from $200 to $210 million.
    The net loss recorded for the quarter end of 2013 was about $69 million and the cash used in operations was $245 million to $255 million. It has also been estimated that the new drug AP26113 is expected to create sales of $1 billion if the clinical trials get successful.

    ARIAD pharmaceutical also conducts regular investors meetings for making corporate presentations. The month of September will witness a series of corporate presentations hosted by ARIAD pharmaceuticals.

    Work culture
    The work culture at ARIAD pharmaceutical has always been very positive with a strong determination of making a remarkable impact in developing drugs effective against cancer. In its journey of almost 2 decades, the firm has received recognition and has been honored with several business awards for outstanding performance. ARIAD pharmaceuticals is a power house of intellectual and passion driven individuals who can strive to any extent to deliver the best and superior quality products for cancer patients.

    The year 2013 has really been an eventful year for ARIAD pharmaceuticals. The firm has been awarded with “The 2013 Ernst and young entrepreneur biotech award” for its entrepreneurs for their exceptional performance in the field of developing wonder drugs to fight cancer. The firm has also been a recipient of “The 2013 Gold Stevie award” for the company of year and “The 2013 Gold Stevie award” for the executive of the year. The Stevie awards are the nation’s premier business awards program.

    Interesting events
    The year 2013 is scheduled to witness some very important events for ARIAD pharmaceuticals.
    • The firm released its second quarter financial results on the 7th of August, 2013. The same day, they also presented the corporate updates for the same year.
    • The annual meeting of European Society of Medical Oncology (ESMO) has been scheduled on 27th of September to 1st of October 2013. This annual event will be held at Amsterdam, Netherlands.
    • The 15th World conference on lung cancer has been scheduled from the 27th to 30th of October, 2013 at Sydney, Australia.

    Recent job openings
    ARIAD pharmaceuticals is always on the hunt for dynamic, passionate and highly qualified individuals who would take their firm to new horizons. Candidates who wish to bring a positive impact in the lives of cancer patients are most welcome to join the firm. Individuals who are hard working, dedicated and passion driven can carry out new research programs and develop new drugs for treating cancers. Interested individuals need to simply drop in their resume and wait for the recruitment process. Individuals can mail their resume at and wait for a call from the recruiters.
    ARIAD pharmaceuticals has several benefit programs for their employees. These include long term equity, stock options, employee stock purchase plan, tuition reimbursement, 401 (K) plan, holidays, paid time off, employee referral bonus, pass for public transportation, insurance of dental health, medical insurance and life insurance. The employees of this firm are also given benefits for short term and long term disability, long term care insurance and employee assistance program.

    0 0

    Celgene is an American biotechnology firm develops pharmaceutical products for battling diseases such as cancer and several inflammatory disorders. This pharmaceutical firm has more than 4,500 employees across the globe and has its headquarters in Summit, New Jersey. The firm has undertaken more than 300 clinical trials for studying the effectiveness of the newly developed drugs.

    The company laid its foundation in the year 1986 and was primarily a part of Celanese Corporation. During this year, the merger of Celanese Corporation and American Hoechst Corporation caused Celgene Corporation to operate as an independent biotechnological firm. Celgene Corporation is mission driven – manufacturing and developing therapeutic products for life threatening diseases such as cancer.

    Celgene Corporation is a member of NASDAQ and S&P 500 component. The firm is traded as CELG and receives royalty from Novartis Pharma for its products of Ritalin family. These drugs are used for treatment of Attention Deficit Disorders.

    Popular biotech products
    The two major biotech products of Celgene Corporation are Thalamid and Ritalin. Thalomid is used for treatment of acute and severe ENL. This drug is indicated in patients with newly diagnosed multiple myeloma. It is also used for maintenance therapy for prevention and suppression of cutaneous manifestations. This drug has also several side effects and should be used with precautions. Females on this drug should abstain from sexual intercourse for at least 4 weeks to avoid getting pregnant. The other popular biotech products include:
    • Pomalyst
    • Vidaza
    • Lifebank USA – for banking of placental and cord blood
    • Revlimid
    • Abraxane
    • Isodax

    Latest discoveries
    Celgene Corporation is constantly carrying out research for developing oral therapies that can be used for treating the disease and not just its clinical symptoms. The scientists and physicians are the pioneers of this corporation and have a major contribution in development of both cell based and small – molecule therapies. These therapies are targeted towards development of drugs that would treat life threatening diseases such as cancer and several inflammatory disease conditions.

    The drugs developed by Celgene Corporation have proved to be very effective against cancer and several other immune inflammatory diseases. However, it needs special mention here that, drugs have their own course of reaction in the body that can cause certain side effects. Side effects reported are deep venous thrombosis and pulmonary embolism. Of the several drugs developed by this firm, pomalyst is one drug that had shown to cause the above mentioned side effects. When clinical trials were conducted with pomalyst, prophylactic anti-thrombotic measures were administered.

    These anti-cancer drugs are contraindicated in pregnancy as they can cause fetal toxicity.

    Recent company takeovers
    Celgene Corporation has participated in several company mergers that have allowed the firm to manufacture and develop pharmaceutical drugs. The firm joined hands with Abraxis Bioscience in the year 2010 and gave birth to the drug Abraxane. The same year witnessed the merger of Celgene Corporation and Gloucester pharmaceuticals which led to the development of Istodax.

    In the year 2012, Celgene and Avila pharmaceuticals signed an agreement for developing targeted covalent drugs aimed for treating cancer and other related disease through protein silencing. The merger of these two firms was worth $350 million. Celgene was also to receive an additional amount of $195 million on approval of AVL 292.

    These products have several immunomodulatory and biological properties that have a pivotal role to play in treatment of cancer. In addition to this, these drugs also have anti – inflammatory and cellular properties that have targeted action towards the tumor cells and other immune-inflammatory diseases.

    Recent corporate news
    Of late Celgene Corporation announced the offering of senior unsecured notes at $1.5 billion. Of these, about $400 million will mature in the year 2018 and will have an interest rate of 2.300%. $700 million will mature in the year 2023 and have interest rate of 4%.

    Work culture
    The work culture at Celgene Corporation is positive and dynamic and the firm is ever striving hard to develop new and innovative therapeutics for treating cancer. It also participates in several programs that offer services to public who have very limited access to medical facilities.
    Celgene considers the employees as its assets. The employees are a diverse group of people consisting of the scientists, PhD, clinical research scientists, lab technicians, regulatory experts, clinical coordinators, financial personnel, nurses, pharmacists and human resource managers. The employers are dedicated and hardworking, who also give their best to develop and deliver pharmaceutical drugs for the millions of individuals across the globe. The diverse group of talented employees allows the company to work in a balanced way.

    Celgene is blessed with choicest of employees who are masters in their respective fields and are highly qualified. The firm provides appropriate training to its employees so that they can grow and take the company to new heights with each passing year.

    Interesting events
    Each year has been a remarkable year for Celgene Corporation. The European Commission granted approval for the drug Pomalidomide in the year 2013. This drug has been formulated for treating patients with relapsed or refractory multiple myeloma, which is a rare form of blood cancer. This drug Pomalidomide is been considered as a novel achievement in the area of drug pharmacy. This drug has been proved to be effective in treating the rare form of blood cancer by preventing its relapse.

    The research data on studies of revlimid in high risk asymptomatic patients with multiple myeloma was published in the New England journal of medicine.

    Recent job openings
    Celgene Corporation is forever on the search for new, dynamic, highly qualified and hard working individuals who can take their firm and its research to new heights. The firm requires hard working employees who can carry out research with full dedication and perseverance. Individuals who have analytical minds and can carry out research for developing innovative products for the benefit of society at large. Interested individuals can drop in their resume and wait for the interview call. The recruiters will screen the individuals for the final selection process.

    0 0

    Additive manufacturing or three dimensional (3D) printing has been the latest rage in the industry for a couple of years now. Its ability to bring an image to life is being explored by engineers and scientists all over the world. The basic technique behind additive manufacturing is that a printer connected to a computer or data source adds layer by layer to create the object desired. For example, if you wanted to create a 3D print out of a pen, you would first have to scan the pen and digitize its image. Then, software would convert the scanned and digitized image into a series of files which will acts as layers. Then the printer print out these files layer by layer which are then joined together by a heating coil to generate a three dimensional print out of the pen. This method is known as fused filament fabrication and is one among the wide variety of processes available for 3D printing.

    Three dimensional printing has a lot of applications however; the most important among them is its use in the field of medicine. It is a widely known fact that when it comes to organ transplants, there aren’t nearly enough donors as there are patients. Almost three decades after its development, additive manufacturing is becoming affordable and therefore, accessible making them the best candidates for development of synthetic organs.

    Biological printing or bioprinting as it is more famously known allows direct digital manufacture of cells onto a biological membrane. The bioprinter has an output that adds cells to a geometrically mapped biological membrane moving left to right, adding the cells where required. The printer moves slowly and steadily adding very thin layers of cells and after a couple of hours it generates an actual desired structure.
    One of the pioneers in this field was scientist Makoto Nakamura who created the first successful bioprinter in 2002. He realized that the drops that are released by an inkjet printer are quite similar in size to an actual cell and set out to make a printer that could print biological materials. He succeeded in producing a bioprinter that prints out biotubing similar to a blood vessel. Almost a year later, Scientist Thomas Boland and his lab at the bioengineering department at Clemson University modified an inkjet printer to accommodate and dispense pre grown cells in scaffolds. Since scaffolds like hydro gels aren’t safe if inserted inside the body, Dr.Gabor Forgacs developed new technology that allowed cells to be printed without scaffolds. His lab has been able to successfully print cells in toroidal patterns and are currently working on tubular and cuboidal structures.

    Another pioneer in the tissue engineering industry, Organovo created a bioprinter based on Forgacs technology. This printer, Novogen MMX bioprinter has two jets- one houses a hydrogel that acts as a temporary support for the cell, other houses a cartridge which contains the bioink. Cells in the bioink are pre-grown in form of spheroids and then added to the cartridge where they form the bioink. The jets add the bioink into the hydrogel and layer by layer a tissue is created. The naturally fused cells are left for incubation and growth in the growth medium and the hydrogel is removed.

    In the first decade of its development, bioprinting has been able to produce blood vessels, cardiac tissue, nerve cells and lung tissue. Another giant in the industry, NovaCopy has successfully printed a 3D plastic prosthetic leg for a duck and hope to achieve similar success with biological materials. This would be a huge accomplishment and a great source of hope for the handicapped. It is extremely hard to find a good prosthetic arm or leg that perfectly matches an individual’s requirements perfectly.

    In spite of the excitement in the industry regarding this new and promising form of regenerative medicine, scientists are asking individuals to hold on to their hearts and not to get carried away in the hype. Bioprinting is a new technology which still needs to be understood, perfected and made accessible. Scientists at various labs all over the world are still learning how to make living cells pass through a print head without killing them. It is said that the world is still looking at a decade or two before bioprinted organs become available for mass use. We also need to figure out how to reduce the time required to generate an actual organ (printing a liver now would take anywhere from 10 hours to more than a day). Despite the warnings and the long wait ahead, you CAN look forward to that day when long waits and exhausting donor lists will be a thing of the past.

    0 0

    Basic Information:
    Marquette is a Catholic Jesuit University located in Milwaukee, Wisconsin. Located on a 93 acre campus in the University Hill district, Marquette offers all of the big city benefits available in Milwaukee. Life on campus at Marquette University offers an endless supply of activities, events and attractions. There are about 250 student organizations through which students can hone leadership skills, develop a commitment to service and deepen faith.

    [Image: 800px-Marquette_University_campus.jpg]

    Marquette began as a dream of the Most Rev. Martin J. Henni, the first Catholic bishop of Milwaukee, but it took a trip overseas to find an investor to make it a reality. Belgian businessman Guillaume Joseph DeBuey promised $16,000 for the proposed "academy of learning." It was hardly enough to fund the establishment of a college but just enough to keep Bishop Henni's dream alive for the next eight years until he could purchase a parcel of land on a hill topping today's North 10th and West State streets.

    Nearly three decades passed before the doors of Marquette College, a small liberal arts school for men named after Rev. Jacques Marquette, S.J., opened on Aug. 28, 1881. Bishop Henni died just two days later, one might guess satisfied that his work was finished. The mission of Marquette University is the search for truth, the discovery and sharing of knowledge, the fostering of personal and professional excellence, the promotion of a life of faith, and the development of leadership expressed in service to others.

    First year students in engineering, nursing, or the first year honors program can live inspecial housing units to develop camaraderie and strong relationships with other students in their respective programs. Mashuda Hall, a sophomore dorm, was once the Coach House Motor Inn, where The Beatles stayed during their tour in 1964.

    Undergraduate Programs:
    Marquette University College of Health Sciences offers an undergraduate degree in the program of biomedical sciences. The biomedical sciences major combines human health sciences with the university's distinctive courses in the humanities and social sciences, and provides the intellectual tools and scientific proficiency to succeed in advanced studies in the health sciences. Undergraduate coursework includes many courses often reserved for graduate students, including histology, pharmacology, and molecular pathology. After completing the biomedical sciences degree program, students should be able to explain fundamental concepts in the major areas of biomedical sciences (anatomy, physiology, biochemistry, microbiology, pathology, pharmacology, and molecular pathology). Students should also be able to demonstrate scientific literacy and apply it to contemporary health care issues.

    The biochemistry and molecular biology major at Marquette University analyzes the molecular structure and chemistry of biological systems. Discoveries in this discipline are revolutionizing our understanding of living systems, with far-reaching implications for fields such as medicine, agriculture and ecology. Marquette’s program in biochemistry and molecular biology provides an environment that supports both scientific and ethical inquiry in the discipline.

    The biology major lives at the leading edge of science, using the latest technology to explore molecular medicine, ecology and the environment, genetic regulation of plant and animal development, microbial physiology and cell dynamics and motility.
    All Marquette biological sciences majors take at least three courses taught entirely in the lab by a professor, not teaching assistants — an opportunity few national research universities provide their undergraduate biology majors.

    Freshman admission requires High school transcript; ACT or SAT test scores from testing organization or on high school transcript, essay, Counselor Recommendation Form and a list of extracurricular activities.

    Undergraduate Tuition: $34,200/year. Marquette offers financial aid in the form of scholarships, grants, and student loans. More than 90% of Marquette students receive some type of financial aid. Students can apply for financial aid by filling out the FAFSAA between January 1st and February 15th.

    Graduate Programs:
    Graduate students in the Biological Sciences program can choose to focus in Biochemistry, Cell Biology, Developmental Biology, Ecology, Genetics, Microbiology, Molecular Biology, Neurophysiology, or Physiology. The biological sciences graduate program at Marquette University aspires to train experimental scientists capable of teaching and directing independent research by providing a broad theoretical background and an appreciation for the rigor of the scientific method. Students are prepared for employment in faculty positions and research posts in academia and industry.

    Marquette University and the Medical College of Wisconsin offer an interdisciplinary program in bioinformatics. The program prepares students for a multidisciplinary career in the biomedical sciences using mathematics, statistics and computer science. It is designed to provide students quantitative tools for analyzing data and problems associated with molecular, cellular, physiological and particularly, genetic systems. Students may select courses from a list of approved courses offered by the following departments at Marquette: Mathematics, Statistics and Computer Science; Biology; Biomedical Engineering; and Electrical and Computer Engineering. In addition, courses are offered by the Department of Physiology and the Division of Biostatistics at Medical College of Wisconsin. Admission to this program requires undergraduate transcripts, three letters of recommendation, and a written statement. GRE scores are strongly recommended.

    The Graduate School at Marquette University offers a biomedical engineering program as well. The biomedical engineering program is interdisciplinary in nature, involving the application of engineering and mathematics to the solution of problems related to medicine and biology.
    Students in the biomedical engineering program can specialize in several different disciplines, including:
    M.S.: Bioinstrumentation/Computers, Biomechanics/Biomaterials, Rehabilitation Bioengineering, Systems Physiology
    M.E.: Biocomputing, Bioimaging, Bioinstrumentation, Biomechanics, Biorehabilitation
    Ph.D.: Bioinstrumentation/Computers, Biomechanics/Biomaterials, Functional Imaging, Rehabilitation Bioengineering, Systems Physiology
    More specific areas of research in the biomedical engineering program include: artificial limbs/prostheses, biomaterials, biotelemetry, cell transport and metabolism, cardiac electrophysiology, computers in medicine, functional imaging, head and spinal cord trauma, hemodynamics, human motion analysis, medical and biological image analysis, physiological signal processing, rehabilitation engineering, systems physiology, telerehabilitation, tissue engineering, hard and soft tissue biomechanics and transcutaneous power transfer. The bioengineering program is also a collaborative effort between Marquette University and the Medical College of Wisconsin.

    Graduate tuition: $1025/credit hour. Graduate students at Marquette University are supported by teaching assistantships or grant-supported research.

    Applied 22,354
    Admitted 12,707 57%
    Enrolled total 2,068
    Full Time: 2,056
    Part Time 12

    Test - 25th % - 75th %
    SAT Reading - 520 - 630
    SAT Math - 530 - 650
    SAT Writing - 520 - 630
    ACT Composite - 24 - 29
    ACT English - 24 - 30
    ACT Math - 24 - 29
    ACT Writing - 8 - 9

    Other Information:
    Undergraduate: Approximately 8300
    Graduate: Approximately 3500
    11 Schools and Colleges
    78 Undergraduate majors and 77 undergraduate minors
    More than 1200 Faculty members
    In the College of Engineering for 2013, the graduate biomedical engineering program was ranked 51st.
    Biological sciences at Marquette ranked as 181st overall and the chemistry program was 140th by US News and World Reports.
    Marquette University has a chapter of the Phi Beta Kappa Honor Society

    Undergraduate Programs and Majors:
    Biochemistry & Molecular Biology
    Biological Sciences
    Biomedical Engineering
    Biomedical Sciences

    Graduate Programs:
    Bioinformatics (MS)
    Biological Sciences (MS/PhD)
    Biomedical Engineering (ME/MS/PhD)
    Neuroscience (PhD)

    Application Deadlines:
    Undergraduate: December 1st
    Graduate: No official deadline; application review begins January 1st; Bioinformatics deadline January 15th

    Applications are submitted online.
    Undergraduate application:
    Graduate application:

    0 0

    Basic Information:
    Oregon State (OSU) is a leading research university located in one of the safest, smartest, greenest small cities in the nation. Situated 90 miles south of Portland, and an hour from the Cascades or the Pacific Coast, Corvallis is the perfect home base for exploring Oregon’s natural wonders.

    As Oregon’s leading public research university, with $281 million in external funding in the 2012 fiscal year, Oregon State’s impact reaches across the state and beyond. With 12 colleges, 15 Agricultural Experiment Stations, 35 county Extension offices, the Hatfield Marine Sciences Center in Newport and OSU-Cascades in Bend, Oregon State has a presence in every one of Oregon’s 36 counties, with a statewide economic footprint of $2.06 billion.

    Oregon State also ranks high in sustainability, fourth among universities nationwide for using renewable energy and first in the Pac-12 Conference. The students at Oregon State University literally help power the university: 22 exercise machines at Dixon Recreation Center are connected to the grid.

    Undergraduate Programs:

    Oregon State University offers a bachelor’s degree in Biological and Ecological Engineering through the College of Engineering. Biological and Ecological Engineering is the application of engineering and life-science principles and problem-solving techniques to the optimum use and sustainability of biological resources. The curriculum is engineering-based with strong emphasis on the life sciences. The Bachelor of Science (BS) in Ecological Engineering degree program offered through the Colleges of Agricultural Science and Engineering is a new degree program that is the first of its kind nationally at the undergraduate level. The undergraduate Ecological Engineering degree program requires completion of 192 credit hours. In addition to the traditional engineering training in mathematics, physics, chemistry, and engineering analysis and design, students in this program will receive training in biology, ecology, geosciences, hydrology, and systems analysis methods. Another important distinction between Ecological Engineering and other engineering disciplines is its strong links to ecology, geosciences, hydrology, and water quality. Students also acquire a general understanding of legal, political, economic, and sociological disciplines. Students that graduate from this program will be firmly grounded in the hard sciences, engineering fundamentals and systems analysis and aware of and sensitive to how other disciplines drive and respond to Ecological Engineering in practice.

    The College of sciences offers bachelor’s degrees in biology, biochemistry and biophysics, and microbiology. Students in the biology program can also choose to complete one of four undergraduate Options in Biotechnology, Genetics, Marine Biology and Pre-Education. The bachelor’s in microbiology program has very successful graduates. Three months after graduation, 95% of recent graduates have been employed in a microbiology-related field or accepted to a program for further education.

    Undergraduate admissions require 4 years of English, 3 years each of science, mathematics, and social studies, and 2 years of foreign language.

    Undergraduate tuition is $6,228/year in-state and $19,944/year out-of-state. Financial aid is available in the form of scholarships, grants, work-study, and loans. Students should complete the FAFSA to apply for financial aid. Undergraduate applications must be submitted by February 1st to be eligible for University scholarship consideration.

    Graduate Programs:
    The Biological and Ecological Engineering Department offers programs leading to the M.S. and Ph.D. degrees. The objective of the department's degree programs are to serve as the interface between life sciences and engineering. Biological and Ecological Engineering is the application of engineering and life-science principles and problem-solving techniques to the optimum use and sustainability of biological resources. The curriculum is engineering-based with strong emphasis on the life sciences. Courses focus on biological systems modeling, theoretical and applied aspects of bioconversion and bioseparation processes, regional hydrologic analysis, groundwater systems, irrigation, water resource optimization, remote sensing, image analysis, and instrumentation. The admission policy for Biological and Ecological Engineering is that students can be accepted into the program at any time during the year and it is possible that support from sponsored research can become available throughout the year. Most students begin this program Fall Term and there are advantages with an early application in terms of assistantships and finding an advisor. It is recommended that student applying to begin in the fall have all materials submitted by January 5th.

    The graduate program in the Department of Biochemistry and Biophysics at Oregon State University grants primarily PhD degrees, but also offers thesis and nonthesis Masters degrees. The program offers a broad range of research topics through the faculty within the department, those associated with the Linus Pauling Institute, and Affiliate faculty from other departments throughout the OSU campus. Research interests of the faculty in the graduate program include cancer biology, aging, amyotrophic lateral sclerosis (Lou Gehrig's Disease), heart and spinal cord development and disease, mouse transgenics, atherosclerosis, protein and nucleic acid structure and function, DNA modification and epigenetics, cell signaling, oxidative stress, micronutrients, bioinformatics, and biosensors. Research in the department is supported by over $2.5 million dollars annually from external grants. The department is well equipped with research facilities that include confocal microscopy, flow cytometry, X-ray crystallography, NMR, mass spectrometry, analytical centrifugation, and computational resources, and is additionally supported through facilities in the Environmental Health Sciences Center and the Center for Genome Research and Biocomputing.

    The Microbiology Program provides graduate training leading towards PhD and MS degrees. The Program supports broad interests in microbiology, including environmental and pathogenic microbiology, with studies that encompass a spectrum of approaches from the ecological and organismal to the molecular genetic and biochemical. Faculty from several colleges and departments participate as major advisors.

    Students accepted into the Department of Biochemistry and Biophysics doctoral program receive financial support in the form of teaching and research assistantships. Graduate students typically receive a twelve-month stipend of $23,000, a full tuition waiver, and a medical insurance plan that also includes dental and vision coverage. Other graduate students are eligible for teaching and research assistantships.

    A minimum GPA of 3.0 to 3.5 is required for admission to graduate programs, along with GRE scores, letters of recommendation, and statements of interest.

    Applied 11,428
    Admitted 9,269 81%
    Enrolled total 3,696
    Full Time: 3,481
    Part Time 215

    Test - 25th % - 75th %
    SAT Reading - 470 - 600
    SAT Math - 490 - 620
    SAT Writing - 0 - 0
    ACT Composite - 21 - 26
    ACT English - 19 - 26
    ACT Math - 21 - 27
    ACT Writing - 0 - 0

    Retention / Graduation:
    Retention rate 81%
    4-year graduation rate 28%
    6-year graduation rate 60%

    Other Information:
    26,393 students from all 50 states and nearly100 countries
    Average 3.56 GPA among the fall 2012 incoming class
    400 acres of historic, beautiful campus and 11,250 acres of college forests
    More than 200 undergraduate degree programs and more than 80 graduate degree programs,
    170,000 alumni
    3,481 world-class faculty

    Undergraduate Programs and Majors:
    Biological and Ecological Engineering (BS)
    Biology (BS)
    Biochemistry and Biophysics (BS)
    Microbiology (BS)

    Graduate Programs:
    Biological and Ecological Engineering (MS, MENG, PhD)
    Biochemistry and PhD (MS/PHD)
    Microbiology (MS/PhD)

    Application Deadlines:
    Undergraduate: February 1st for scholarship considerationssss
    Graduate: January 15th

    Application is available online:

    For graduate programs, you may contact the specific department for application requirements.

    0 0

    Bio-Rad laboratories developed in 1952, continues to deliver the best innovative tools in clinical diagnostics and scientific research to the world. With a global team of over 7,300 employees, this company provides services to more than 100, 000 research and industry customers. It has its headquarters in Hercules, California.

    Bio-Rad has hands on expertise on development of new and innovative technology that would be of use in genomics, medical field, food safety, drug discovery, medical diagnostics and proteomics. The firm has built strong customer relationships that would pave way for improved and advanced scientific research and also help in development of new and innovative diagnostic tools.

    The life science research technologies of Bio-Rad includes electrophoresis, microbiology, protein functional analysis, amplification, transfection, droplet digital PCR, multiplex immunoassay and chromatography. Bio-Rad has been listed in the NYSE as BIO and BIOb.

    Popular biotech products
    The products of Bio-Rad are considered as “gold standard” for diabetes monitoring and QC – quality control systems.

    The Bio-Rad products provide a great deal of support to the researchers across the globe. The life science research group of Bio-Rad develops, manufacturers as well as promotes a wide variety of instruments, consumables and apparatus that would benefit the researchers and consumers at large.

    The group of clinical diagnostics of Bio-Rad develops, manufactures and markets products for laboratory diagnosis. The diagnostic products developed and manufactured by this firm have turned out to be a boon for detecting, identifying and quantifying substances in body fluids and tissues. These products help a great deal in diagnosis, identification and treatment of various medical diseases and conditions.

    Latest discoveries
    Bio-Rad laboratories have made a significant contribution in the areas of microbial testing, food science, process separations, clinical diagnostics and life science education. The rapid chromogenic media for testing the microbial quality of foods has enabled the rapid testing of food samples. To add to this, the water testing kits developed by the firm has enabled rapid testing of the microbial quality of water.

    The Bio-Rad TSE testing products have been around since the time of BSE crisis aroused in Europe. The TSE testing products include reagent kits, equipments and software.

    Of late, the firm introduced New iQ – Check Prep system for Automated Real - time PCR detection of food pathogens. This latest discovery of Bio-Rad has made detection of food pathogens possible by automating sample preparation. The sample is then detected by real - time PCR. It also released its very new food pathogens testing kits – iQ-Check STEC VirX and SerO kits. The VirX kit is used for detection of Shiga toxins that produce E coli. The SerO kit is meant for detecting Shiga toxins that produce E coli of O157:H7, O26, O45, O103, O121 and O145.

    Amongst food testing kits, Bio-Rad laboratories developed, iQ - Check S. Enteritidis kit for the rapid detection of Salmonella Enteritidis using the real – time PCR method. This method helps identify the presence and enumeration of Salmonella Enteritidis in egg and poultry samples in just a few hours.

    Bio-Rad laboratories are also expected to launch cell sorter that would enable advance research in the area of cell analysis. A test panel for celiac disease will also be introduced in the year 2013.

    Recent company takeovers
    The year 2002 witnessed the collaboration of Bio-Rad and Quantase Ltd. of Perth, Scotland. Quantase Ltd specializes in diagnostic tools for screening of newborn diseases. It has been estimated that the current market for newborn screening tests will reach $100 million across the world and will increase by 10% each year.

    In the beginning of 2013, the company joined hands with AbD Serotec that would facilitate the firm to carry out more advanced research with antibodies.

    Recent corporate news
    The Bio-Rad stock price recorded for August 13, 2013 was $117.10. For the year 2010, the company had revenues exceeding $1.9 billion. The sale for the year 2012, was around $2.1 billion which was a bit lower than what was recorded for the year 2011.

    Work culture
    The work culture at Bio-Rad is dynamic with a positive environment. The employees are the heart and soul of the company and it is through their dedication and hard work that the firm has received the much needed success and achievements. The employees of Bio-Rad laboratories give in their best to churn out superior quality products for the world at large. The products developed by this firm have made research easier and they can devote more time in developing quality products for a global clientele.
    Bio-Rad considers its employees as its assets who are ready to undertake any task for taking the firm to new defined avenues.

    Interesting events
    Bio-Rad laboratories has been celebrating its diamond anniversary. Following this, there are many other interesting events that have taken place in the past as well as in the current year.
    • The company reports its second – quarter final financial reports.
    • It also introduced the QX200 Droplet Digital PCR system.
    • In the year 2012, The USDA gave no objection letter for Bio-Rad’s method for STEC detection in beef.
    • Bio-Rad also received approval from AOAC for iQ-Check for Campylobacter detection.
    • In the same year, the NF validation was renewed for 2 real – time PCR kits for detection of E coli O157:H7 and Salmonella.
    • Qualitative test kits for infant formulae and environment samples also received the NordVal approval.

    Recent job openings


    Bio-Rad laboratories is always on the hunt for new and vibrant individuals who can strive hard to take the company to new heights. The company is always open for hard working and dedicated individuals with an analytical mind. Such individuals can conduct high quality research and deliver best and superior products to customers worldwide. Job openings for various positions are available and interested candidates can drop in their resume. Individuals can even upload their resume at the company’s website and wait for the recruitment process. Bio-Rad laboratories also has special summer internship package for individuals. Interns are given state – of –the-n art experience with equipment, instruments and facilities. The firm has also made special provisions for paid internships in the fields of engineering, biochemistry, quality control, environmental health and safety, information technology, research and development.

    0 0

    Basic Information:
    Washington University in St. Louis (Wash. U., or WUSTL) is a private research university located in suburban St. Louis, Missouri, United States. Founded in 1853, and named after George Washington, the university has students and faculty from all 50 U.S. states and more than 120 countries.

    Washington University is made up of seven graduate and undergraduate schools that encompass a broad range of academic fields. Officially incorporated as "The Washington University," the university is occasionally referred to as "WUSTL," an acronym derived from its initials. More commonly, however, students refer to the university as "Wash. U." To prevent confusion over its location, the Board of Trustees added the phrase "in St. Louis" in 1976.

    The Department of Biology has received national recognition for the contributions of its faculty in genetics, neuroscience, development, population biology, plant biology, and other areas of specialization. Work being done in the Department has broad implications for the treatment of disease and genetic anomalies, the preservation of endangered species, the development of food crops, and many other global problems centered in the life sciences. The Biology Department has a distinguished history, highlighted by the 1986 Nobel Prize awarded to two former members of the department, Rita Levi-Montalcini and Stanley Cohen, for their discovery at Washington University of the Nerve Growth Factor. Today, the Department includes four professors who are members of the National Academy of Sciences and many others who have gained international distinction for their research.

    Undergraduate Programs:
    The College of Arts and Sciences at Washington University St. Louis offers an undergraduate program through its biology program. Several tracks are offered for biology majors, including evolution and ecology; genomics and computational biology; molecular biology and biochemistry; and neurosciences. Students wishing to complete the neuroscience track apply for admission during their sophomore year at Washington University St. Louis. A student graduating with a major in biology should be well educated in the history of scientific discovery in biology, the logical and statistical procedures used to formulate and to test biological hypotheses, and technical skills needed for conducting contemporary biological research. The Department of Biology also offers an undergraduate major in environmental biology.

    The Department of Biomedical Engineering offers a four-year curricular leading to a professional baccalaureate degree, a Bachelor of Science in Biomedical Engineering (BS) which is designed to prepare students for graduate school, medical school or industry. The BS in Biomedical Engineering is accredited by the Engineering Accreditation Commission of ABET, Graduate level courses are open to qualified, upper level undergraduates. These courses offer advanced training in selected areas of bioimedical engineering.

    Freshman applicants are eligible to apply for the University Scholars Program in Medicine, which offers dual admission to Washington University St. Louis for undergraduate and medical school.

    Undergraduate tuition: $40,950/year. WUSL offers merit-based scholarships to students who show exceptional aptitude. Loans and grants are also available to students for financial assistance.

    Graduate Programs:
    The Division of Biology and Biomedical Sciences offers 12 PhD programs. The programs are: Biochemistry; Computational and Molecular Biophysics; Computational and Systems Biology; Developmental, Regenerative, and Stem Cell Biology; Evolution, Ecology and Population Biology; Human & Statistical Genetics; Immunology; Molecular Cell Biology; Molecular Genetics and Genomics; Molecular Microbiology and Microbial Pathogenesis; Neurosciences; and Plant and Microbial Biosciences.

    The graduate program in the Department of Biology and Biomedical Sciences is unique from other graduate programs. In a traditional graduate program, a student might be one of a few dozen working in a narrowly defined department. At Washington University in St. Louis, graduate students are admitted to a Division of 500 students and more than 330 faculty members from 31 departments who teach and work in programs on both the hilltop and medical campuses. This organization fosters interaction among Programs, students and faculty. What boundaries exist are easily and regularly crossed. The Division serves scientists and their work. Each student receives personal attention, and the course of study is customized as his or her education requires.

    The School of Engineering offers a program in biomedical engineering for either a master’s of science degree or PhD. PhD students must complete a core curriculum, fulfill a distribution requirement, satisfactorily complete two research rotations, pass the qualifying examination and complete a research dissertation. The master’s degree program offers both a thesis and non-thesis option.

    Admission to graduate programs varies based on programs, but students should in general have four years of science, at least two years of mathematics, four years of English, and four years of a foreign language. GRE scores, transcripts, and letters of recommendation are required for admission.

    Tuition: $40,950. Most full-time graduate students are eligible for financial assistance through teaching or research assistantships.

    Continuing Education:
    Washington University in St. Louis offers education to adults through its University College of Arts and Sciences. Master’s and bachelor’s degrees, as well as certificates, are available in Clinical Research Management. The program also offers a master’s of science in Applied Health Behavior Research.

    University College offers a post-baccalaureate degree for students preparing to apply to medical school. The Post-Baccalaureate Premedical Program (Post Bac Pre Med) at Washington University in St. Louis enables qualified college graduates to take core and elective science and math courses that satisfy medical school admission requirements. Students may take approved elective courses in natural sciences, social sciences, and humanities that provide a broad context and skill set for the practice of medicine today. The program is flexible to support students who need most or all medical school prerequisites, as well as those who have completed most or all of those prerequisites but need additional preparation. Admission to the program requires transcripts, a 500-word essay, a current resume, and 2 letters of recommendation.

    Applied 28,823
    Admitted 4,763 17%
    Enrolled total 1,488
    Full Time: 1,488
    Part Time 0

    Test - 25th % - 75th %
    SAT Reading - 690 - 760
    SAT Math - 710 - 780
    SAT Writing - 0 - 0
    ACT Composite - 32 - 34
    ACT English - 32 - 35
    ACT Math - 32 - 35
    ACT Writing - 0 - 0

    Retention / Graduation:
    Retention rate 97%
    4-year graduation rate 84%
    6-year graduation rate 93%

    Other Information:
    90 Degree Programs, almost 1500 Courses
    19 Washington University graduate and professional programs in top-10 rankings (Us News and World Reports)
    Six major world rankings of leading universities include Washington University in the top 12% and 5 of the 6 place the university in the top 10% of universities in the world.

    Undergraduate Programs and Majors:
    Biology (BS)
    Environmental Biology (BS)

    Graduate Programs:
    Biochemistry (PhD)
    Computational and Molecular Biophysics (PhD)
    Computational and Systems Biology (PhD)
    Developmental, Regenerative, and Stem Cell Biology (PhD)
    Evolution, Ecology, and Population Biology (PhD)
    Human & Statistical Genetics (PhD)
    Immunology (PhD)
    Molecular Cell Biology (PhD)
    Molecular Genetics and Genomics (PhD)
    Molecular Microbiology and Microbial Pathogenesis (PhD)
    Neurosciences (PhD)
    Plant and Microbial Biosciences (PhD)
    Biomedical Engineering (PhD)

    Dual Degree Programs:
    University Scholars Program in Medicine (BS/MD)
    Biomedical Engineering MS/MBA
    Physician Scientist MD/PhD

    Application Deadlines:
    Undergraduate: November 15th, Early Decision; January 15th, Regular Decision
    Graduate: Division of Biology and Biomedical Sciences: December 1st
    Biomedical Engineering: January 15th
    WUSL accepts the common application, available at:

    0 0
  • 08/22/13--20:23: Biogen Idec
  • Biogen Idec

    Biogen Idec started operations in the year 1978 and is first amongst the very few biotechnological company of its time. With more than 30 years of experience, this firm is continuing its research to bring out drug therapies for the public at large.
    Biogen Idec with its varied pharmacologic drugs is striving hard to make a positive impact in the lives of people with unmet medical needs. This company is based on two basic principles – bio and technology; bio is life and technology is the conversion or the practical application of ideas into processes. This firm is a member of NASDAQ and is traded as BGEN.
    Biogen Idec matured as a company with developing drugs for multiple sclerosis. Its other areas of expertise include neurodegenerative disorders, autoimmune diseases, rheumatoid arthritis and hemophilia. Two years after its conception, the company made its first breakthrough with the discovery of biologically active human leukocyte – α interferon and human fibroblast – β interferon. In the same year, Walter Gilbert, PhD, research scientist and founder of Biogen Idec was one amongst the three scientists to have received Nobel Prize in Chemistry for understanding the sequencing of DNA.
    The year 1986 was a year of real success for Biogen Idec. It was in this year that the first product – INTRON developed by the scientists of this firm was introduced in the market.
    Popular biotech products
    Biogen Idec began its journey by adopting the disease multiple sclerosis that had no known effective medications in that era. It was an ignored disease condition left alone by pharmaceutical companies, and Biogen Idec made its first entry into the market with development of an effective drug known as AVONEX for treating multiple sclerosis (MS). Some years down the line, the company came out with yet another drug for MS known as TYSABRI. Years passed by and Biogen Idec continued to make a positive impact in the field of pharmaceutical drugs and in the process two new drugs were introduced in the market - RITUXAN and FAMPYRA.
    Latest discoveries
    Biogen Idec has constantly come out with new and innovative drug therapies for helping patients with deadly diseases. The following list speaks of some of the latest drug discoveries by this company.
    • TECHFIDERA for treating relapsing episodes or forms of multiple sclerosis. This drug has received FDA approval.
    • PLEGRIDY – yet to receive FDA approval and is used for treating relapsing forms of MS.
    • RECOMBINANT FACTOR IX Fc for treating hemophilia B.
    • RECOMBINANT FACTOR VIII Fc for treating hemophilia A.
    • GA101 for treating non – Hodgkin’s lymphoma.
    • TYSABRI for treating MS – secondary progressive form.
    • OCRELIZUMAB for treating relapsing form of MS.
    • ANTI-TWEAK for treating lupus nephritis.
    • ANTI-LINGO for treating MS.
    • STX – 100 for treating idiopathic pulmonary fibrosis.
    • NEUBLASTIN for treating neuropathic pain.
    • SMN for spinal muscular atrophy
    • CD40L for treating systemic lupus erythematosus.
    • BIIB037 for treating Alzheimer’s disease.
    The last two drugs in the above list are still in the phase I of clinical trials and are yet to enter the next stage of drug testing.
    Recent company takeovers
    Biogen Idec is committed to deliver world class therapies for several neurodegenerative diseases. Forming partnerships and alliances with more than one firm is one amongst the four success pillars of this firm. Biogen Idec has collaborated with same firms multiple times to deliver therapies that can have a promising effect on neurodegenerative disorders.
    Biogen Idec entered into collaboration with Elan Pharmaceuticals to develop the TYSBARI drug. The firm has collaborated with Abbott, Acorda, Genentech, Isis pharmaceuticals, Knopp Biosciences, NsGene A/S, Portola pharmaceuticals, Samsung, UCB S.A. Ltd., Roche and Neurimmune therapies.
    Biogen Idec has signed agreement with Isis pharmaceuticals for 3 times in a row. This agreement will view the development of RNA – targeted drug discovery. With this, the Isis – SMNRx was developed for the treatment of spinal muscular atrophy.
    Biogen Idec entered into collaboration with Samsung and Stromedix in the year 2012. This joint venture led to the development of STX-100.
    Recent corporate news
    The total revenue of Biogen Idec for the year 2012 was $ 5,516 million. The GAP net income for the same year was $ 1,380 million and diluted earnings for shares was 5.76. In the year 2013, the firm has allocated about $20 million for their innovation fund.
    Work culture
    The work culture at Biogen Idec is very positive and one has to actually be a part of this firm to experience and believe it. The employees of this firm strive extremely hard and leave no stone unturned for developing and delivering best therapies for the common man.
    The employers of Biogen Idec are good paymasters and strive to provide their employees the best of everything. The employees are given rewards and recognition for the work done and are applauded for the wonder discoveries in pharmacy. The firm provides compensation for the employee’s health, provides competitive compensation, and also provides several benefits package for its employees. It also promises a secured financial future for its employees in form of 401 (K) savings plan, college savings (529 plans) and employee stock purchase programs.
    Interesting events
    Every passing year continues to be interesting and eventful for Biogen Idec. The following list speaks of some of the most interesting events that took place in recent years.
    • In the year 2011, the firm announced the positive results from phase III clinical trials for the oral drug BG-12.
    • In the year 2012, Biogen Idec donated about $349 million for free drug patient program. It also provided about $2 million to support in fellowship programs.
    • The firm also provided a grant of $1.6 million in 2012 for the development of various educational and community – based programs.
    Recent job openings
    Biogen Idec is constantly on the lookout for vibrant and dynamic individuals who can take their firm to greater heights. Interested candidates can drop in their resumes and wait for their turn in the recruitment process. Biogen Idec needs qualified candidates who are passionate enough to research and develop new drug therapies to serve mankind. Individuals can even upload their resumes at the Biogen website. They can also take a short tour through the website to understand the working and functioning of this firm.

    0 0

    Basic Information:
    Iowa State is an international university with a friendly welcoming personality. Students from all 50 states and more than 100 countries come to Ames, Iowa, to choose from 100 majors, study with world-class scholars and hone their leadership skills in 800-plus student organizations. Iowa State offers a great environment where students can enjoy reaching their potential and discovering their passions.

    Iowa Agricultural College and Model Farm (now Iowa State University) was officially established on March 22, 1858, by the legislature of the State of Iowa. Story County was selected as a site on June 21, 1859, and the original farm of 648 acres was purchased for a cost of $5,379. The Farm House, the first building on the Iowa State campus, was completed in 1861, and in 1862, the Iowa legislature voted to accept the provision of the Morrill Act, which was awarded to the agricultural college in 1864. Iowa Agricultural College (Iowa State College of Agricultural and Mechanic Arts as of 1898), as a land grant institution, focused on the ideals that higher education should be accessible to all and that the university should teach liberal and practical subjects. These ideals are integral to the land-grant university.

    Undergraduate Programs:
    The Biological Sciences department at Iowa State University offers many different biotechnology majors. Students can major in Biochemistry, Bioinformatics and Computational Biology, Biological Systems Engineering, Genetics, and others.

    Outstanding faculty and facilities in the biological sciences provide opportunities that students won’t find anywhere else. The biochemistry faculty received federal funding for research in such areas as nutrition, x-ray crystallography of proteins, nuclear magnetic resonance spectroscopy, and modern biotechnology procedures. The Lawrence H. Baker Center for Bioinformatics Biological Statistics computational, graphical, and algorithmic methods to interpret data from biological studies.

    The Department of Biochemistry, Biophysics, and Molecular Biology (BBMB) offers a combined program that allows students to obtain two separate degrees, both the Bachelor of Science and Masters of Science, in as few as 5 years. The combined degrees can be useful to students entering various career tracks. For those considering careers as research specialists, entry positions with higher-level responsiblities, and a higher-level salary, are made possible with the M.S. degree. For those considering careers as research directors, which require advanced study, the M.S. degree provides an advantage for admission into Ph.D. programs at the most competitive and prestigious graduate schools. Similarly, the M.S. degree can be a competitive advantage for admission in to medical, dental, law, veterinary medicine, or other professional schools. The M.S. thesis requires intensive experience in original, independent laboratory research, which is a significant benefit in any of these career tracks.

    The best preparation for studying at Iowa State University continues to be a strong college preparatory program of study, which includes courses in English, mathematics, laboratory science, social studies, and foreign languages. Freshman students can elect to live in BEST housing (Biology Education Success Teams) to be near other students studying similar subjects. There is also a wide variety of student clubs for those studying biological sciences.

    Undergraduate tuition: $6408/year in-state; $18,280/year out-of-state. Need-based financial aid is available to students by filling out the FAFSA. Iowa State also offers scholarships, grants, and loans for financial aid. Undergraduate students may also participate in faculty sponsored research.

    Graduate Programs:
    The Roy J. Carver Department of Biochemistry, Biophysics & Molecular Biology at Iowa State University offers a variety of graduate degrees. They offer a PhD in Biochemistry or Biophysics. The program requires about 5 years on average of graduate level study to complete. The majority of a student’s time is spent doing research on his or her dissertation project, although considerable time also is devoted to advanced coursework and professional seminars. The dissertation research project is undertaken in the laboratory of a faculty mentor, under her or his close supervision. The program also offers training in the teaching of biochemistry at the undergraduate and graduate levels. Almost all students receive financial support in the form of a research assistantship. A thesis-based master’s degree in science is also available.

    The Bioinformatics and Computational Biology Graduate Program provides an interdisciplinary research environment where successful collaborations between life science researchers and computational scientists have developed over its 12 year history. PhD study in ISU's BCB Graduate program gives students a vibrant learning community supported by world class resources. Entering students enjoy full tuition and health insurance credits, as well as a yearly stipend which can range up to $25,000 depending on the fellowship received.

    The College of Veterinary Sciences department of biomedical sciences offers graduate programs to students. Areas of research include: Fundamental neuroscience; Neurotoxicology; Immunology; Vaccine development; Infectious diseases; Cell biology; Nutrition; Development and mechanisms of learning and memory; Auditory processing; and Aquatic biology. Students can attain a non-thesis master’s degree, a thesis master’s degree, or a PhD.

    Iowa State University established the first graduate program in biorenewable resources and technology in the United States. While other universities offer certificate programs or minor programs related to biobased products and bioenergy, ISU offers M.S. and Ph.D degrees in this new field, as well as a minor for students obtaining degrees in other majors and a certificate.

    The Immunobiology program emphasizes interdisciplinary education with specialization appropriate to the student's interests. The master's degree requires 30 credit hours, and the doctoral degree requires 72 credit hours. The Graduate College requires that Ph.D. candidates pass preliminary examinations. A master's degree is not a prerequisite to a Ph.D. Research is an integral part of the curriculum in Immunobiology at Iowa State University. A student will select a major professor from the faculty participating in the program. The role of the major professor is to act as a mentor and will guide the student's professional development. Both M.S. and Ph.D. candidates must prepare and defend a thesis.

    Graduate tuition: $7476/year in-state; $19,192/year out-of-state. Tuition and health insurance are covered by most PhD programs.


    Applied 15,066
    Admitted 12,135 81%
    Enrolled total 4,552
    Full Time: 4,528
    Part Time 24

    Test 25th % 75th %
    SAT Reading 460 640
    SAT Math 530 670
    SAT Writing 0 0
    ACT Composite 22 28
    ACT English 21 28
    ACT Math 22 28
    ACT Writing 0 0

    Retention / Graduation:
    Retention rate 88%
    4-year graduation rate 36%
    6-year graduation rate 70%

    Other Information:

    8 Colleges, 2 Schools, and 57 Academic Departments
    More than 100 undergraduate majors
    Iowa State University recently has been designated as a Collaborating Center for the
    World Health Organization in the area of food safety and research.
    Enrollment: 31,040 (fall 2012)
    Faculty & staff: 6,300
    Alumni: 227,022

    Undergraduate Programs and Majors:
    Biochemistry (BS)
    Bioinformatics and Computational Biology (BS)
    Biological Pre-Medical Illustration (BS)
    Biological Systems Engineering (BS)
    Biology (BS)
    Biophysics (BS)
    Environmental Science (BS)
    Food Science (BS)
    Genetics (BS)
    Microbiology (BS)

    Graduate Programs:
    Biochemistry (MS/PhD)
    Bioinformatics and Computational Biology (PhD)
    Biomedical Sciences (MS/PhD)
    Biophysics (MS/PhD)
    Biorenewable Resources and Technology (MS/PhD)
    Genetics (MS/PhD)
    Immunobiology (MS/PhD)
    Microbiology (MS/PhD)
    Molecular, Cellular and Developmental Biology (MS/PhD)

    Dual Degree Programs:

    Biochemistry, Biophysics, and Molecular Biology (BS/MS)

    Application Deadlines:
    Undergraduate: Students should apply fall of their senior year of high school.
    Graduate: Varies by department, but generally January 15th

    Applications are completed online.
    Graduate: Applications are available through each independent department.

    0 0
  • 08/26/13--02:49: Analysis of DNA Sequence
  • Hello everyone,
    I have one problem in a mini project please help me.
    I have some bacterial colonies and I knew their are some changes in their genetic structure but not able to know how to know from which part I should extract DNA and go for further steps.
    I will be highly thankful to you all for guiding me.

    0 0

    Basic Information:
    In 1817, the University of Michigan was established in Detroit and became the first public university in the Northwest Territories. A grant of 1,920 acres from three Great Lakes Indian nations was earmarked for the nascent institution. In 1837, the same year in which Michigan became a state, the University relocated to Ann Arbor to take advantage of an offer by local entrepreneurs of 40 acres of land at the edge of town. The acreage ceded by the Indians was sold, and the proceeds remain part of the University’s permanent endowment.

    The University of Michigan-Flint opened in 1956 with a gift from the Mott Foundation. The University of Michigan-Dearborn followed in 1958 on the land of the Henry Ford Estate, a gift of the Ford Motor Company.

    The University of Michigan is a global leader in health, law and public policy, the arts and humanities, science and technology, and many other academic disciplines. The essence of the University is the academic diversity of the schools and colleges, many of which are among the best in the country, and the degree of interdisciplinary cooperation among them. The schools of Business, Education, Engineering, Information, Law, Medicine, Music, Nursing, Public Health, and Social Work are ranked among the best in the country.

    Undergraduate Programs:
    The undergraduate Program in Biology encompasses a breadth of disciplines spanning all levels of organization and includes the study of a diversity of organisms. The program offers 7 majors, which are: Biology, Cellular and Molecular Biology, Ecology and Evolutionary Biology, General Biology, Microbiology, Plant Biology, and Neuroscience. Students are strongly encouraged to begin taking early biology classes as soon as possible upon entering the University of Michigan in order to prepare to declare their major. The Biology major program develops an appreciation of the levels of organization of life, its diversity, and the processes by which life has achieved its present forms. The program is recommended for those who wish to study biology as part of a liberal education, to prepare for a teaching career in secondary schools, or to prepare for graduate study in biology or the health professions. The curriculum in Cellular and Molecular Biology offers students an integrated program of study and training in the biological and physical sciences. It is a pathway to graduate study in areas of biology and medicine that emphasizes a quantitative and analytical approach to the life sciences.

    There is also a 5 year program available for students to obtain a bachelor’s degree and master’s degree in cellular and molecular biology and biomedical engineering. This program is designed for students enrolled in the College of Literature, Science and the Arts. The program is jointly administered by the Department of MCDB (College of LS&A) and the Biomedical Engineering (BME) Department (College of Engineering). A matriculating student will receive the B.S. in Cellular and Molecular Biology (CMB) from the College of LS&A and a M.S. in Biomedical Engineering (BME) from the College of Engineering. Students will be admitted to the program only after completing the first year of major prerequisites with a grade point average of 3.2 or higher. Admission to the program must be approved by advisors from the Departments of MCDB and BME.

    Understanding how brains process information and generate behavior is one of the most challenging questions in the life sciences. The neuroscience concentration, sponsored by the Departments of MCDB and Psychology, provides training that integrates studies in cell and molecular biology, physiology and behavior. An undergraduate degree in neuroscience provides the background for a career in brain research, and also serves as excellent training for students interested in medicine or other health professions.

    Undergraduate tuition: $12,440/year in-state; $37,588/year out-of-state

    Graduate Programs:
    The Program in Biomedical Science (PIBS) at the University of Michigan School of Medicine coordinates admission for 14 graduate programs. The departments under the PIBS umbrella include: Bioinformatics; Biological Chemistry; Biophysics; Cancer Biology; Cell & Developmental Biology; Cellular & Molecular Biology; Human Genetics; Immunology; Microbiology & Immunology; Molecular, Cellular & Developmental Biology; Molecular & Cellular Pathology; Molecular & Integrative Physiology; Neuroscience; and Pharmacology.

    The MCDB Master of Science degree is a non-thesis, non-research based degree, however, some master's students work in laboratories for course credit. The program consists of twenty-four hours of course work; this includes at least sixteen hours of MCDB courses at the 400 level or above and at least four hours in a cognate subject. This program is flexible and serves a variety of career objectives such as teaching in secondary schools, employment in a variety of research-oriented jobs, and preparation for further professional training. The department does not provide funding for Master's students. In addition, the Pathways Program is a two-year thesis-based Master's program, providing students with the research- and course-related training necessary to succeed in a top-flight Ph.D. program. The Pathways program will enable students to gain critical research experience in MCDB labs towards the ultimate completion of a research-based Master's thesis.

    The University of Michigan Bioinformatics Graduate Program (BGP) is the academic component of the Department of Computational Medicine and Bioinformatics (DCM&B). The BGP was established as an interdepartmental program in 1998 at the University of Michigan, and enrolled its first class in 2001. The Bioinformatics Graduate Program is led by co-directors Dr. Margit Burmeister, Professor of Psychiatry and Human Genetics and Dr. Daniel M. Burns Jr., Professor of Mathematics. This Program is highly interdisciplinary involving many different schools and departments across the U-M campus. There are over 100 faculty members affiliated with the program. In addition, it maintains a graduate student body of approximately 45 Ph.D. and Master's students combined.

    The general Graduate Record Examination (GRE) scores, a statement of research interests and experience, and three letters of recommendation are necessary as part of the formal application as well as transcripts from all academic institutions attended.

    Graduate tuition: $18,666/year in-state; $37,726/year out-of-state
    All graduate students in the PIBS program who are in good academic standing are supported financially throughout the duration of their graduate studies. Each student receives tuition, an annual stipend of $28,500 and healthcare benefits.

    Applied 39,584
    Admitted 16,073 41%
    Enrolled total 6,236
    Full Time: 6,211
    Part Time 25

    Test 25th % 75th %
    SAT Reading 630 730
    SAT Math 670 770
    SAT Writing 650 750
    ACT Composite 29 33
    ACT English 29 34
    ACT Math 28 34
    ACT Writing 0 0

    Retention / Graduation:
    Retention rate 96%
    4-year graduation rate 73%
    6-year graduation rate 89%

    Other Information:
    3 Campuses
    Schools and colleges: Ann Arbor, 19; Dearborn, 4; Flint, 5
    Total enrollment, Fall 2011: 59,933
    Instructional staff, all campuses, Fall 2010 (includes graduate student instructors): 8,791

    Undergraduate Programs and Majors:

    Graduate Programs:
    Bioinformatics (MS/PhD)
    Biological Chemistry (MS/PhD)
    Biophysics (MS/PhD)
    Cancer Biology (MS/PhD)
    Cell and Developmental Biology (MS/PhD)
    Cellular and Molecular Biology (MS/PhD)
    Human Genetics (MS/PhD)
    Immunology (MS/PhD)
    Microbiology and Immunology (MS/PhD)
    Molecular, Cellular, and Developmental Biology (MS/PhD)
    Molecular and Cellular Pathology (MS/PhD)
    Molecular and Integrative Physiology (MS/PhD)
    Neuroscience (MS/PhD)
    Pharmacology (MS/PhD)

    Dual Degree Programs:
    5 yr BS/MS in Cellular and Molecular Biology and Bioengineering

    Application Deadlines:
    Undergraduate: December 1st, early admission; February 1st, regular admission
    Graduate: December 1st

    Applications can be completed online.
    Undergraduate: Completed via the Common Application, available at:

    0 0

    Basic Information:
    The nation’s pioneer land-grant university, MSU began as a bold experiment that democratized higher education and helped bring science and innovation into everyday life. The revolutionary concept became a model for the nation. Today, MSU is one of the top research universities in the world—on one of the biggest, greenest campuses in the nation. Home to nationally ranked and recognized academic, residential college, and service-learning programs, MSU is a diverse community of dedicated students and scholars, athletes and artists, scientists and leaders.

    MSU ranks in the top 100 on the Top Universities by Reputation 2013 list published by Times Higher Education. The list—which looks solely at the reputations of institutions for teaching and research—is based on responses to an invitation-only survey from nearly 17,000 academics at institutions in 144 countries worldwide. MSU is the only university in the country with on-campus medical schools graduating allopathic (MD) and osteopathic (DO) physicians, as well as veterinarians. As the university extends the College of Human Medicine and the College of Osteopathic Medicine to new areas of the state, MSU will be among the largest universities in the United States in terms of the number of medical school graduates. Rankings compiled at the University of Western Australia list MSU among the top 50 universities in the world based on research performance, including publications and citations. These rankings also list MSU among the top 50 universities in the categories of arts, humanities, business, and social sciences and engineering, computing, and technology and in the top 100 in the areas of medicine and the health sciences and pure, natural, and mathematical sciences.

    Undergraduate Programs:
    Michigan State University offers an undergraduate degree in Biosystems Engineering. Combining biology with engineering, biosystems engineers make sure we have our daily essentials: safe and plentiful food to eat, pure water, clean energy sources, and a safe environment to live in.
    The undergraduate program in Biochemistry and Molecular Biology is characterized by strong preparation in chemistry, molecular biology and biochemistry, emphasizing practical training in marketable laboratory skills. Undergraduates can enhance their education and training through independent research mentored by BMB faculty.

    The Human Biology curriculum has strong foundations in the core biological disciplines of biochemistry, anatomy, physiology, cell biology and genetics. To complement the core curriculum, students are able to choose from several upper level biology elective courses offered through the College of Natural Science. Human Biology elective credit can also include directed study, internship, and/or research experiences in biological and physical science. In addition, the Capstone Tier II Writing requirement (NSC 495) allows students, through their writing and oral presentations, the opportunity to integrate their knowledge of the disciplines in the core curriculum during the senior year.

    The Department of Microbiology and Molecular Genetics offers three Bachelor of Science degree programs: one in Microbiology, one in Genomics & Molecular Genetics, and one in Environmental Biology/Microbiology. The objective of the undergraduate major in Microbiology and Molecular Genetics is to provide a broad foundation in science with an emphasis in microbiology. Classically, microbiology is defined as the study of microbes, small living organisms. The faculty members take a more contemporaneous view and our definition includes the study of the biology of all prokaryotic and eukaryotic cells and their viruses. Thus, the Microbiology and Molecular Genetics major at MSU is designed to be appropriate for students interested in any area of biology, regardless of the careers or subdisciplines they plan to pursue.
    Freshmen applicants should have 4 years of English, 3 years of math, 3 years of social studies, 2 years of science, and 2 years of foreign language.

    Undergraduate tuition: $12,908/year in-state; $33,796/year out-of-state. Financial aid is available; students should complete the FAFSA to apply for aid. All admitted students are automatically considered for scholarships. In most instances, the application for admission, including the required personal statement, are sufficient for award consideration.

    Graduate Programs:
    The Cell and Molecular Biology graduate program at Michigan State University is an interdepartmental PhD program with participating faculty from many different departments and administrative units. The research programs address a wide variety of biological questions with an equally diverse array of organisms. However, they are all related in their dependence upon the ideas and approaches common to cell biology and/or molecular biology. These common approaches unite the research programs of the participating faculty whether they are interested in herbicide resistance in crop plants, DNA replication in bacteria, or tumor development in humans.

    The Genetics Graduate Program at Michigan State University is one of the outstanding graduate programs for genetics research and scholarship in the country. The strength of the program lies in its interdisciplinary nature, allowing graduate students a great deal of flexibility in designing their individualized programs of research and study while maintaining a core PhD graduate program and strong interactions among students and faculty.

    A PhD program is offered called the Interdisciplinary Graduate Studies in BioMolecular Science program. The BioMolecular Science Gateway offers admission to 6 graduate programs: Biochemistry and Molecular Biology, Cell and Molecular Biology, Genetics, Microbiology and Molecular Genetics, Pharmacology and Toxicology, and Physiology. Students have access to training in over 150 research laboratories in the fields of biochemistry, cancer, cell biology, genomics, genetics, immunology, microbiology, molecular biology, pharmacology, toxicology, physiology, plant molecular biology, structural biology, and virology. Students rotate through the laboratories of potential Ph.D. mentors and take coursework appropriate to their disciplinary interests. In the spring semester of the first year, students have the opportunity to select the Ph.D. program that aligns most closely with their educational goals. Most students take about 5 years to complete a PhD.

    Graduate tuition: $13,656.00/year in-state; $26,820.00/year out-of-state. The graduate stipend for 2013-2014 PhD students is $25,480. Tuition costs and health insurance are also covered. Outstanding students are eligible for generous supplemental funds as well as the MSU Distinguished Fellowship Program.

    Applied - 28,416
    Admitted - 20,728 - 73%
    Enrolled total - 7,984
    Full Time: - 7,827
    Part Time - 157

    Test 25th % - 75th %
    SAT Reading 440 - 600
    SAT Math 540 - 670
    SAT Writing 450 - 600
    ACT Composite 23 - 28
    ACT English 22 - 28
    ACT Math 23 - 28
    ACT Writing 0 - 0

    Retention / Graduation:
    Retention rate 91%
    4-year graduation rate 49%
    6-year graduation rate 77%

    Other Information:
    200 programs of undergraduate, graduate, and professional study
    Freshman class profile (middle 50 percent of fall 2012 entering class): high school GPA, 3.4–3.9; SAT combined score (math and critical reading), 1020–1220; ACT composite score, 23–28
    More than 275 study abroad programs on all continents in more than 60 countries
    An ever-growing library collection approaching seven million print volumes

    Undergraduate Programs and Majors:
    Biosystems Engineering (MS)
    Biochemistry and Molecular Biology (BS)
    Human Biology (BS)
    Microbiology (BS)
    Genomics and Molecular Genetics (BS)
    Environmental Biology/Microbiology (BS)

    Graduate Programs:
    Cell and Molecular Biology (PhD)
    Biochemistry and Molecular Biology (MS/PhD)
    Cell and Molecular Biology (MS/PhD)
    Genetics (MS/PhD)
    Microbiology and Molecular Genetics (MS/PhD)
    Pharmacology and Toxicology (MS/PhD)
    Physiology (MS/PhD)

    Dual Degree Programs:

    Application Deadlines:

    Undergraduate: November 1st for maximum scholarship consideration
    Graduate: December 1st

    Undergraduate application:
    Graduate application:

    0 0

    Substances that are capable of enhancing the response of the immune system to the antigen are termed as Adjuvants. They can also be substances that enhance the effect of a drug on the body. The history of Adjuvant can be traced back to 1920s, when French biologist, Gaston Ramon revealed that the response of antitoxins to tetanus and diphtheria was amplified by injection of these vaccines, along with other substances such as lecithin, agar, starch oil, saponin, and breadcrumbs. Adjuvants are mainly utilized in organisms that are used to raise antibodies by injecting the antigen. The net effect is to stimulate a larger and more prolonged generation of the antibody.

    Adjuvants exercise their action in various ways. Some Adjuvants retain the antigen and so present the antigen to the immune system over a long period of time as the immune response does not occur all at the same time, but relatively is continuous over a longer period. An Adjuvant also by itself can react with some of the cells of the immune system and this interaction may fuel the immune cells for heightened reaction. Adjuvants can also increase the recognition and ingestion of the antigen by the phagocyte. This increased phagocytosis presents more antigens to the other cells that form the antibody.

    Adjuvants are chemically greatly heterogeneous set of compounds having a common ability of enhancing the immune response. The Adjuvants such as aluminium phosphate, aluminium hydroxide and calcium phosphates are commonly utilized for human use. Other varieties of adjuvants include cholesterol, endotoxins, aliphatic amines, fatty acids, gram-negative bacteria or products derived from bacteria, liposomes and vegetable oils. In the recent years compounds such as SAFs (syntax adjuvant formulations consisting of muramyl dipeptide or threonyl derative), ISCOMs with Quil-A, and monophosphoryl lipid A are under evaluation for utilization in human vaccine.

    Immunopotentiators or vaccine Adjuvants have gained plentiful consideration as important ingredients of vaccine for the current and future. At present times in most of the countries worldwide aluminium salts (alum) remains as the only approved adjuvant for human use with few exceptions.

    0 0

    Forest laboratories is a pharmaceutical firm aimed at developing therapeutic drugs for the treatment of various kinds of diseases. Reaching out to the unreached and meeting the medical needs of the unmet is the motto of this firm.

    Forest laboratories took birth in the year 1954 and has its headquarters in New York City, US. It is traded as NYSE and has more than 5,600 employees. The firm also operates from various other cities of St. Louis, Oakland, Dublin, Paris, Kent, Jersey City and Cincinnati. Forest ranks as one of the top 50 pharmaceutical companies worldwide (Pharmaceutical Executive magazine, May 2013)

    "Our strategies would be without value if it were not for the thousands of employees who help to create and bring life to our company. It is due to their tenacity, skill, and hard work that we owe our success" is what the Howard Solomon Chairman, CEO & President says.

    Popular Biotech products

    These diverse ranges of therapeutic products are meant for treating various disease conditions such as disorders of the central nervous system, respiratory, endocrinology, respiratory diseases, anti – infective therapeutics, gastrointestinal and obstetrics.

    Latest discoveries
    The company’s main goal is to serve the public at large by developing innovative therapeutic drugs for various disease conditions. With this motto, Forest Laboratories is constantly innovating new products and conducts 3 phases of clinical trials for testing the efficacy of these products.

    The following is a list of products that have been recently developed for treating disease conditions such as various infectious diseases, pulmonary disorders, cardiovascular diseases, Alzheimer’s disease, COPD – chronic obstructive pulmonary disease and mental health disorders.
    • Cariprazine for treating bipolar disease
    • Bystolic valsartan for treatment of hypertension
    • Tudorza for treating COPD
    • Azimilide indicated for treatment of arrhythmia – irregular heart beats
    • Ceftazidime for treating infectious disease conditions
    • Namendra for treating Alzheimer’s disease

    All the above mentioned drugs have either been approved by the NDA or have completed the phase III of clinical trials.

    Recent company takeovers
    Forest laboratories is a mid – sized firm that develops and markets therapeutic products covering a wide range of diseases. The firm has entered into partnerships with several other firms for expanding its business as well as widening its area of research to develop the best drugs for the world at large. Acquisitions and merger helps a firm to enter into new research areas and develop products that can be beneficial for the public.

    Work culture
    The work culture at Forest laboratories is pretty positive and vibrant with an enormous group of energetic employees who are ready to undertake any task with passion. With each collaboration, the firm works in a close knit fashion with its partners to make sure the end product is flawless and one of its kind. The firm considers its employees as its strength and pillars of success.

    Forest laboratories also offer its employees a number of benefits that is enough for financially securing their future. These benefits include profit sharing program and the 410 (K) plans. It also has special provision for holidays and vacations for its employees so that they can take rest and recharge their minds and body for delivering the best to the company and in turn to the society at large. The firm also offers several family benefit programs that include new mom and baby programs, parental leave, adoption and fertility assistance program, so and so forth.

    Interesting events
    Forest laboratories is constantly striving to deliver the best therapeutic products for treatment of various disease conditions. These continuous efforts have caused them to always be in the limelight that has given them the much needed attention and success. The following is a list of interesting events for the current year - 2013.
    • The firm in partnership with Almirall decides to delay the NDA filing of a drug – Aclidinium.
    • Forest laboratories together with Pierre Fabre laboratories announce the FDA approval of Fetzima that is indicated for treatment of depressive disorders in adults.
    • The firm reported its fiscal year first quarter 2014 diluted earnings value of $0.09 per share.
    • The firm in the current year announced the positive results of the phase III clinical trial for the drug Nebivolol and valsartan in combination for treatment of hypertension.
    • The current year – 2013 also witnessed the availability of new once – daily Namendra X.
    • In the month of June, 2013, the firm appointed its new independent director and also provided a detailed report on the succession planning.
    • In the month of May, 2013, Forest laboratories presented its data on the clinical trials of the drug Aclidinium Bromide and Roflumilast at the International conference of American Thoracic Society (ATS).

    Recent job openings
    Forest laboratories is open for experienced and vibrant individuals who with their hard work and research skills would take the firm to fathomable heights in the future. The interested candidates can drop in their resume at The firm also has several provisions for seasonal internship programs for students and also for experienced professionals. Forest offers a variety of opportunities and career paths that span a broad spectrum of strengths, expertise, and interests. If you would like to build your career with a company that is consistently recognized in industry rankings as a top pharmaceutical company.
    The following are the available positions for the professionals:

    -Pharmaceutical Sales Representative - Palm Springs, CA (Field/Remote)
    -Pharmaceutical Sales Representative - Grapevine, TX (Field/Remote)
    -Associate Business Information Manager - (NJ - Jersey City)

    Individuals are requested to apply with the job id mentioned on the company’s website. They can also search the careers and opportunities section in the website and click on the available and preferred positions for more details on a specific opening or position. Selected candidates will be called for an interview and will be screened as per the company’s recruitment process.

    0 0

    Medivation is a biopharmaceutical firm committed to develop innovative therapies for treatment of serious diseases. The firm has come as a hope to individuals suffering from various diseases for which very limited treatment options are available. The firm was developed by an expert team of individuals who had previously been part of a pharmaceutical firm. Medivation was set up with the goal of development of therapies for treatment of severe illnesses and medical devices that can help early detection of diseases.

    The company has its headquarters in San Francisco and has more than 300 employees. Medivation got its first product approved in the year 2012.

    Popular biotech products
    XTANDI is the most popular biotech product of Medivation. This drug is indicated in patients with metastatic castration – resistant prostate cancer (mCRPC). Xtandi is solely meant for men and should in no way be used by women. Pregnant women and women of child – bearing age should also refrain from using this drug.

    Though the use of this drug has proved to be effective for patients with prostate cancer, but this drug has also shown to have some side effects. These include back ache, fatigue, arthralgia, hot flush, edema, musculoskeletal pain, insomnia, dizziness, hematuria, anxiety, hypertension, lower respiratory tract infection, cauda equina syndrome and paresthesia.

    Xtandi works by decreasing the tumor volume, induces death of the cancer cells and arrests as well as decreases cell growth. This drug in no way causes decrease in the levels of androgen, but works by inhibiting the binding of androgen to its receptors.

    Latest discoveries
    The scientists at Medivation are constantly striving to create new drugs for the treatment of diseases such as prostate cancer and breast cancer. The drug Xtandi has been developed for treatment of prostate cancer. The company in partnership with Astellas is in the process of developing enzalutamide for various stages of prostate and breast cancer.

    Recent company takeovers
    Medivation realizes the importance of partnerships and therefore enters into collaboration with various pharmaceutical firms for widening its area of research as well as developing several therapeutic products for treating life threatening diseases like cancer. In the year 2009, the firm joined hands with Astellas to develop and market enzalutamide. The collaboration was worth $110 million. Astellas would be responsible for developing the drug and marketing it and has also agreed to pay royalty to Medivation on the aggregate net sales of enzalutamide outside US.
    Several efforts are also been made to test the efficacy of enzalutamide for the more advanced stages of prostate and breast cancer.

    Recent corporate news
    Medivation has been a member of the NASDAQ and is traded as MDVN. The last stock price was 56.53 on the 30th of August 2013.

    Work culture
    Medivation considers its employees as its assets and the work environment in this firm is very fast paced and vibrant. The employees of this firm strive hard to conduct research and develop new and innovative therapies for treating deadly disease conditions. They are extremely confident and committed group of people who can take the company to new horizons. Employees at Medivation can go to any extent to serve the public at large by developing beneficial drug therapies.

    Interesting events
    The firm is always up for various interesting events and is an active participant in many conferences. The Morgan Stanley Global Health Conference is scheduled on the 10th of September, 2013.
    Medivation has also taken part in two conferences in the month of August, 2013. These were Wedbush 2013 Life Sciences Management Access Conference and Medivation second quarter 2013 financial results conference call.

    Recent job openings
    Medivation is forever on the search of vibrant individuals with analytical minds who can deliver their best to the world and also are ready to undertake challenges. Interested individuals can drop in their resume and wait for the recruitment process. The following is the list of career opportunities with Medivation.

    -Accounting, finance: There are several positions available in this field; such as director, tax, senior accountant, senior manager and senior financial analyst. For these positions, individuals need to have more than 10 years of experience in tax and relevant accounting. They should also have working knowledge on the several tax related subjects.
    -Biometrics: The positions available are manager, clinical data manager, and senior statistical programmer. For these, the individuals need to have at least 7 – 10 years of experience in oncology studies and also have a basic knowledge of SAS.
    -Clinical development: The positions in this field include clinical project manager, director of drug safety, manager of drug safety and clinical research associate. In order to apply for this position, the candidates need to undergo training in GCP and should have 2 years of experience in clinical research.
    -Medical affairs: The available positions for this field include medical director and senior director of medical affairs. The individuals need to have at least 3 – 5 years of experience in pharmaceutical company and also have 2 years of experience in medical affairs. They also need to possess professional knowledge and skills in oncology.
    -Medicinal chemistry: The available position for this field is associate director who are required to support the research work and the developmental activities and set goals for future work. The individuals need to have more than 6 years of experience in small molecule and drug discovery and its development.
    -Pharmaceutical operations: Stability manager in pharmaceutical operations need to have at least 5 years of experience in GXP research laboratory. They also need to have experience in working with CMOs in a virtual environment.
    -Pre clinical: The positions available in this field constitute of senior director, administrative assistant and associate director, and predictive diagnostics. For these positions, the individuals need to have experience that would suit each area of expertise. For applying for the post of administrative assistant, the individuals should have 5 – 7 years of experience as an administrative professional and should be an expert in operating Ms Office. For applying for the post of senior director, toxicology, the individuals should have 15 years of experience in a pharmaceutical industry and should have expertise in handling PhD level staff.

    0 0

    Alexion pharmaceuticals is a biopharmaceutical firm founded in the year 1992, aimed at developing innovative drugs for treatment of severe, deadly and rare disorders. The scientists of Alexion were the first to unlock the terminal component of a group of proteins that plays a vital role in the body’s immune system. These proteins if not controlled can even lead to destruction of healthy tissues.

    The first product developed by this firm was Soliris. This product is indicated in treatment of paroxysmal nocturnal hemoglobinuria (PNH) and the drug is approved in more than 40 countries. Alexion pharmaceuticals has it’s headquarter in Cheshire, Connecticut.

    Popular biotech products
    Soliris (eculizumab) is the drug meant for treating patients with paroxysmal nocturnal hemoglobinuria (PHN). This drug has received FDA approval and is the first of its kind to unblock the terminal component of proteins. PHN is characterized by hemolysis – rapid destruction of red blood cells. It is a life threatening and progressive disease that can cause damage to the body’s vital organs such as kidneys and heart. The major and acute complications of this disease include kidney failure, heart attack and ultimately death.

    The work Soliris is basically target – based. It works by attacking that part of the protein cascade which if activated in the wrong manner can give rise to a series of reactions inside the body that can lead to PHN.

    Recent company takeovers
    The firm has acquired its success and achievements through hard work and through mergers and acquisitions with various firms. Mergers and acquisitions with various companies allows the parent company to expand its area of research and in a way widen its drug development work.
    The firm’s first acquisition was in the year 2000, when it joined hands with Proliferon Inc., another biopharmaceutical firm at $ 41 million. This firm was then renamed as Alexion Antibody Technologies Inc. Proliferon firm could produce indefinite amount of antibodies which was the major reason of its acquisition by Alexion Pharmaceuticals.

    In the year 2011, Alexion entered into a merger with Enobia Pharma Corporation at $610 million which was paid at the time of merger. Later on a sum of $470 million was to be paid as contingent on company sales. The firm Enobia developed drug known as asfotase alfa which is used for treating genetic disorders such as hypophosphatasia.

    Recent corporate news
    Alexion became the member of NASDAQ – 100 in the year 2011. In the same year it had market value of $ 8.5 billion due to which it replaced the Genzyme Corporation.

    Work culture
    Alexion is an equal opportunity employer. The work culture in this firm is very positive and vibrant. The company is on the constant look out for individuals who would carry their firm to newer heights.

    The firm provides a variety of benefits for its employees. The benefits include employee assistance program, tuition assistance, flexible spending accounts, 529 college savings plan, insurance for automobile and homeowners, prescription drug coverage, 410 (K) plan and long term disability plan.

    Interesting events
    The firm Alexion is constantly in the limelight due its constant efforts to bring out the best drugs through great research work. Its work has been acclaimed due to its wonder discoveries that have made possible the treatment of severe life threatening diseases.
    The year 2013 has been an eventful year for Alexion pharmaceuticals. The following is the list of events that have taken place for this firm:
    • The firm announced its second quarter results in this year.
    • This wonder drug – Soliris received positive opinion from the Committee for Orphan medicinal products for the treatment of NMO. The drug Soliris also received the title of “Orphan drug”.
    The year 2012 was also a year of real achievement for Alexion pharmaceuticals. It was in this year, that the firm was honored with the title of “Biotech’s New Innovation Powerhouse”. In the same year the firm received the second rank in the annual list of “The World’s Most Innovative Companies”.

    Recent job openings
    The company is on a hunt for young, committed, experienced and dynamic individuals who with their research skills and hard work can take their firm to new, unfathomable heights. The current positions available include marketing, clinical development, research, support functions and manufacturing. Interested candidates are asked to investigate the company’s website and look out for the job vacancies. The following is a list of job opportunities for the candidates:
    Job opportunities in Birmingham
    • Regional account manager
    Job opportunities in Cambridge
    • Associate director
    • Manager
    • Medical director
    • Senior financial analysts
    • Senior statistical programmer
    • Manager regulatory liaison
    Job opportunities in Cheshire, CT
    • Associate director – corporate communications, corporate GxP audit, drug product manufacturing, global clinical supply, global medical value assessment, sourcing, regulatory affairs, non clinical PK/PD/DM.
    • Director regional clinical specialist
    • Customer operations representative
    • Data integration engineer
    • Developmental scientist
    • Director us marketing
    • Director internal audit, internal communications, global hematology marketing.
    • HR systems administrator
    • Manager, corporate quality
    • Manager, internal audit, regulatory liaison, regulatory operations.
    • Research associate
    • Research scientists – molecular sciences, protein sciences
    • Senior director – global information security
    • Senior manager – global market research, clinical quality assurance, hematology marketing
    • Senior statistical programmer
    Job opportunities in Las Vegas
    • Regional accounts manager - biotechnology, oncology and hematology
    Job opportunities in Orlando
    • Regional accounst manager – biotechnology, oncology and hematology
    Job opportunities in Providence
    • Regional accounts manager – oncology, pharmaceutical sales and biotechnology
    Job opportunities in Raleigh
    • Regional accounts manager – oncology, hematology sales and biotechnology
    Job opportunities in Smithfield
    • Associate director – process automation and maintenance and building services
    • Engineer I
    • GMP trainer
    • Maintenance and instrumentation technician
    • Manufacturing associate I, II and III
    • Manufacturing specialist
    • QA engineer and specialist
    • QC analyst I - stability, IV – technical services
    • QC equipment technician
    • Validation technician
    • Senior quality engineer

    Interested candidates can apply for the above jobs based on their educational qualification and experience in the respective fields. It is also advised that the individuals be vigilant about the job openings and should apply either through email or by posting their resume at the website. Selected candidates will be called upon for an interview and if selected will be screened for the final selection process.

    0 0

    Centocor biotech was founded in the year 1979 and is now renamed as Jassen Biotech. It is a biotechnology company that was developed with the aim of manufacturing new diagnostic assays. The year 1982 witnessed the development of the first diagnostic test product of the company which had also received FDA approval. The diagnostic test kit was used for detecting the rabies virus. In 1998, the firm sold off its diagnostic division to Fuirebio, Inc.

    Popular biotech products
    The firm’s first biotech product was the diagnostic test kit for testing the rabies virus. The firm also markets the product ReoPro that is indicated for treatment of coronary angiography.

    Another drug known as Remicade developed by Centocor is indicated in patients with plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, spondylitis, ulcerative colitis in children and ankylosing spondylitis.

    Other products by this company include the following:
    • Simponi Aria
    • Simponi golimumab
    • Stelara
    • Procrit epoetin alfa – is used in treatment of anemia due to chronic kidney disease conditions.
    • Doxil – is indicated for patients with cancer
    • Zytiga

    Latest discoveries
    The firm received FDA approval in the year 2013 for Simponi aria which is used as an infusion for treating patients with rheumatoid arthritis. In the same year the firm released the drug Ibrunitib indicated for treatment of 2 β – cell malignancies.

    Yet another drug named Simponi Golimumab received FDA approval on 16th of may 2013. This drug is indicated in patients with ulcerative colitis.

    In the year 2012, the US FDA approved the expansion of the drug Zytiga for treatment of metastatic castration – resistant prostate cancer.

    Recent company takeovers
    The firm has entered into collaborations with several other firms for extending its area of research and widening the product development plant. The following is a list of the company’s acquisitions that has enabled it to take part in new research and clinical trials for development of drugs and diagnostic tools for the world at large.
    • In the year 2008, the company entered into partnership with Ortho Biotech Inc, and thus gave birth to Centocor Ortho Biotech, Inc.
    • The year 2010, Centocor Ortho Biotech joined hands with RespiVert. This merger opened new avenues for development of small molecule drugs and inhalation therapies for treatment of pulmonary diseases.
    • It was in the month of June, 2011, that the company was rechristened as Jassen Biotech, Inc due to its global merger with Janssen Pharmaceutical Companies.

    Recent corporate news
    Centocor was acquired by Johnson and Johnson which raised the company’s annual sales from $500 million to much more than $2 billion. This acquisition, also caused increase in the investment in research and development from $75 million to $300 million.
    In addition, in the year 2000, the Dutch plant of this firm saw an expansion with an investment of about $250 million. In the year 2007, the Centocor introduced its first very own advertising film known as Innerstate for marketing the drug Remicade.

    Work culture
    The work culture at Centocor is very professional and at the same time quite friendly. The company considers its employees as its assets and rewards them for their hard work and achievements. Employees love to work in such an environment. They work very hard to develop innovative drug therapies for treating deadly disease conditions.

    Interesting events
    Since the time of its inception each year has been a successful year for Centocor Inc. The firm has several achievements to its credit through its constant research and development. The year 2013 has been an eventful year for the drug IBRUNITAB. The following is a list of interesting events of the company:
    • In the year 2013, the research results on the drug Ibrutinab were published in the New England Journal of Medicine. The results revealed that this drug was 68% effective when given to patients with relapsed or refractory mantle cell lymphoma.
    • In the same year, the firm released the phase II data of Ibrunitab. The drug was found to be effective against relapsed or refractory mantle cell or diffuse large β – cell lymphoma.
    • Richer Petty joined hands with the firm for launching the prostate cancer awareness program.
    • The drug ibrunitab received designations from the U.S. Food and Drug administration for third breakthrough in the field of oncology.
    • The follow up data for the drug Zytiga shows that this drug is successful in delaying the progression of metastatic castration – resistant prostate cancer in patients who have received chemotherapy as part of the treatment regime.
    • The firm submits reports for approval of Stelera in the US and Europe. This drug is indicated for treatment of active psoriatic arthritis.
    • The firm released its phase III findings of the drug Stelera in the year 2012. The results revealed that this drug significantly decreased the symptoms of active psoriatic arthritis.
    • In the year 2012, Centocor released the phase III findings of the drug intravenous glomimumab. This drug is indicated in conditions of active rheumatoid arthritis and significantly inhibited the radiographic progression in these patients.
    • The firm Centocor announced the development and commercialization of JAK inhibitor for immunological diseases.

    Recent job openings
    The firm has a powerhouse of experienced professionals, but at the same time more and more people are required to carry the good work forward. For more information, individuals can visit the website and keep an eye on the vacancies section. If any vacancies related advertisement is spotted they can drop in their resume and wait for their screening process. The recruitment of experienced candidates is an on-going process.

    For students who wish to work with this firm must have a full time degree program and should have received any of these degrees – BA, BS, MA, MS, PhD in the past 1 year. Centocor seeks vibrant and passionate individuals who are willing to work hard and are eager to achieve something in their career. Students are recruited only during selected months of the year – August and November. But, those who wish to apply for an internship program can apply during the months of December and February.

    0 0

    Caprion pharmaceutical was established in the year 1998 in Montreal (Canada) and mainly provides proteomics biomarker and target identification services to the world at large. Through its 10 years of integrated approach, it develops in – vitro diagnostics for diseases such as diabetes, infectious diseases, oncology and disorders related to the central nervous system. It also has developed several drug target therapies such as the oncology – cell surface targets and vaccine for various infectious diseases. It has its headquarters in Montreal, Canada.

    [Image: cci.gif]

    Popular biotech products
    One of its most popular biotech products in the area of target discovery is CellCarta. This is a spectrometry which is gel free and it also has label free mass. This allows comprehensive measurement of protein across huge sets of biological samples. The firm also develops various pharmacodynamic biomarkers for testing the drug efficacy, determination of drug dosage, safety aspects and mechanism of action. It also develops several disease markers for diagnostic purpose and surrogates for clinical response to therapies. Its area of expertise also lies in development of predictive biomarkers for testing the efficacy, safety and clinical outcome.

    Latest discoveries
    The firm has developed novel technologies of protein biomarkers that facilitate the process of decision making and clinical development. Of its latest discoveries, the company has developed shigabams for the treatment of bacterial infections caused due to shiga toxin.

    Caprion pharmaceutical has active programs, mainly in 3 broad areas: infectious diseases, oncology and metabolic disease. The areas under study for infectious disease include tuberculosis, brucellosis, vaccine response and dengue. Under oncology, the firm develops products for lung cancer, breast cancer, prostate cancer and neuro - endocrine cancer. For metabolic diseases, the firm manufactures products for β – cell mass function, diabetes drug response and insulin resistance.

    Recent company takeovers
    Caprion pharmaceuticals has attained its success and achievements with sheer hard work and subsequent collaboration with other firms. In the year 2007, the firm joined hands with Thallion pharmaceuticals for intensifying its field to development of novel technologies for oncology and infectious diseases.

    In the year 2005, the firm entered into joint collaboration with ICOS Corporation for widening its area of research. This collaboration leads to the development of therapeutic antibodies for treating cancer.
    Caprion pharmaceuticals also entered into partnership with several other firms such as Abbott laboratories, Biogen Idec, AstraZeneca, Pfizer, Merk & Co and ortho clinical diagnostics.

    Work culture
    The work environment at Caprion pharmaceuticals is dynamic and at the same time very positive. It encourages the staff to produce new and innovative methods that would be useful for the public at large. The firm is a proud owner of a strong and dynamic team of workers.

    The firm gives credit of it success and achievements to its team workers and considers them as their assets. Caprion pharmaceuticals is on the constant look out for young and dynamic individuals who can take the firm to new horizons.

    Interesting events
    Caprion pharmaceuticals has received several awards and recognition due to its achievements in the field of pharmacy. The following list speaks of the achievements the company has received.
    • The firm has received award a 5 – year $ 12.9 million contract for conducting research in the area of infectious diseases. It has received the award by National Institute of Allergy and Infectious disease.
    • It has been awarded a 3 – year contract worth $2.3 million by the CQDM for discovery and validation of biomarkers.
    • In collaboration with Takeda the firm is carrying out a program for identification of proteins that has been secreted from visceral and abdominal fat.
    • The firm is also conducting a neuro – endocrine tumor program. This program is carried out in partnership with INCI. It is receiving funds from CQDM and Alsace – Bio valley. This program would primarily focus on discovery as well as validation of biomarkers for neuro – endocrine cancers.

    Recent job openings
    The firm is forever on the hunt for individuals who are logical and analytical in their thinking. The following is a list discussing about the various areas of expertise required by Caprion pharmaceuticals.
    1. Controller: In this, the individual will have to prepare reports and support the development, implementation as well as the maintenance of the necessary procedures. Applications for this position would require individuals to have more than 10 years of experience and preferably be a chartered accountant.
    2. Scientific director: The individual is in a way representative of both the business and scientific aspects of the firm. They would handle the overseas operations and conduct research as and when required. For applying as a scientific director, the individuals need to be doctorate in immunology and should have more than 10 years of experience.
    3. Bioinformatics specialist: Individuals need to have experience in the field of bioinformatics, flow cytometry and proteomics. They are also responsible for documentation of work flows and implementation of quality control measures as well. For applying for the post of bioinformatics specialist, the individuals need to have experience in programming language such as C, C++ and Java. They also need to effectively use SQL and ORACLE.
    4. Biosample operations manager: The individual is responsible for organizing and maintaining a detailed orientation of all the operational activities concerned with collection, shipment and delivery of biosamples. They need to have a degree in DEC and should have experience in site qualification, lab manual writing and working with LIMS. The candidate should also be able to communicate effectively, have influential skills, and have experience with Microsoft excel.
    5. Flow cytometry technician: The individual is responsible for ensuring that the technical systems in the cytometry laboratory are working efficiently and accurately. They also need to maintain a proper documentation of the cytometry lab reports. For applying to the post of flow cytometry technician, the individual should have experience in the field of cytometry and should possess knowledge of LSR II and Diva software. The individual should also have an expertise in solving both hardware and software related problems of cytomtery. It is also necessary, that the individual should be able to handle and work efficiently under pressure.

    0 0

    Celera Corporation, founded in the year 1998, is a firm devoted to health care business. Molecular diagnostic products are developed and manufactured by this company to be used by the clinical laboratories and hospitals to detect, manage and treat disease conditions. The firm has joined hands with Abbott Laboratories for distribution and commercialization of various molecular diagnostic products developed by it.

    In the year 1998, the firm was a business unit of Applera. From there it grew up to be an independent company in the year 2008. Three years hence, the company was finally acquired by Quest Diagnostics in 2011.
    It is a member of NASDAQ and is traded under the name of CRA.

    Popular biotech products
    Celera Corporation develops products for treatment of infectious diseases such as HIV. One of its popular products in this regard is the ViroSeq HIV-1 genotyping system that is meant for detecting HIV genomic mutations. This product has also been proved to be useful for managing patients with HIV-1 in whom the drug therapies have failed to show the desired effect.

    The next most effective product is a diagnostic device developed for diagnosing the genotyping assay in cystic fibrosis. This device is named as the cystic fibrosis genotyping assay. This innovative device can also be used as a new born screening tool, career screening in adults of reproductive age group and as a confirmatory diagnostic tool in children and newborns.

    The AlleSEQR HLA PCR/sequencing kits and AlleSEQR Heterozygous Ambiguity Resolution Primers are developed to provide high resolution identification of human alleles.

    Latest discoveries
    The Celera Corporation is constantly making new discoveries in the area of both diagnostic tools as well as pharmaceutical products. The firm carries out deep studies in several disease areas such as coronary heart disease, thrombosis, lung disease, liver diseases, CNS, breast cancer, stroke and autoimmune disorders.

    Recent company takeovers
    Celera Corporation is ever ready to partner with several other firms for expanding their business which would in a way also help widen their areas of research. The company invites those firms that wish to partner for a long term relationship and also those who are interested in great scientific research and positive patient outcomes. Interested firms can contact them at for a prosperous and long term future with Celera Corporation.

    Work culture
    The work culture at Celera Corporation is vibrant and offers very positive environs for its employees. The company is a powerhouse of passionate individuals who can go to any extent to deliver the best diagnostic tools and pharmaceutical products to the world. Not just this, the company also rewards its employees for their excellent performance at work both financially as well as securing their future through several beneficial packages.

    Interesting events
    Celera Corporation has joined hands with Abbott laboratories for marketing Celera’s CE – marked KIF6 diagnostic test kit. This diagnostic test kit will detect the genetic marker that is associated with individuals who are at a risk of falling prey to coronary heart diseases.

    Celera Corporation has signed a license agreement with the University of California and has given rights to conduct in – house test for the KIF6 gene test kit in their laboratories. It would be the first time that such a test will be performed outside the Corporation.

    Recent job openings
    Celera Corporation is always on the lookout for individuals who with their research skills can take the company to new avenues. Job openings are available and individuals need to apply for the specific job based on their experience and educational qualifications. A job id has been provided against all the jobs and the individuals need to apply accordingly. Below is a list of job opening along with the corresponding id.

    Job title Job id Location
    Rep, Phlebotomy Services - position in client office in Goldsboro
    3717862 1006a W H Smith Blvd
    Analyst, Workforce - NOC- Tampa, FL
    3717859 4225 E Fowler Avenue
    Rep, Client Service I - Lenexa, KS
    3717856 10101 Renner Blvd
    Rep Phlebotomy Service - CA
    3717563 15 Altarinda Rd
    Route Service Rep - Gainesville, FL - M-F 11am-7:30pm (2nd shift)
    3717718 825 NorthWest 23rd Ave.
    Technician, Medical II - in client office position located at our Cary facility
    3717622 201 Commonwealth Ct
    Rep, Phlebotomy Service - in client office position located in Columbia area
    3717331 3010 Farrow Road
    Group Lead, Phlebotomy Service
    3717791 14050 Town Loop Blvd
    Floater, Phlebotomy Service - covers the Winston-Salem Patient Services territory
    3717413 3726 Vest Mill Road
    Rep, Phlebotomy Services - in client office position located in the Cumming area
    3717370 Multiple Locations
    Rep, Phlebotomy Svcs - Part-Time 25 hours/week - Winter Springs, FL
    3716934 1132 E. State Road 434
    Analyst, Workforce - NOC - Lenexa, KS
    3717855 10101 Renner Blvd
    Rep, Phlebotomy Services
    3717319 750 W Plymouth Ave
    Rep, Phlebotomy Services (30 hr position)
    3717695 4509-009 St. Johns Avenue
    Rep, Route Service - Miramar, FL - 2nd shift - Mon-Sat
    3717516 10200 Commerce Parkway
    Rep, Phlebotomy Service - in client office position located in St Simmons area
    3717064 6555 Abercorn St
    Mgr, Reporting Administration & Development - Collegeville, PA
    3717833 Collegeville Main
    Senior Database Administrator
    3717848 MedPlus REMOTE - Nationwide
    Hospital Account Executive - Washington, DC
    3717815 1901 Sulphur Spring Road
    Oncology Account Manager - Orlando, FL
    3717817 541 E.Horatio Ave
    Accounting Intern - MedPlus
    3717853 4690 Parkway Drive
    Senior Database Administrator
    3717848 MedPlus REMOTE - Nationwide
    Rep, Phlebotomy Services II, West Mifflin PA area, MTh 4a-12:30p, T,W,F 6a-12:30p, plus rota Sat
    3717402 1907 Lebanon Church Road
    Rep, Phlebotomy Svcs I - CA
    3717637 1600 Creekside Drive
    Technician, Specimen I, Night Shift 8:30pm -5am, M-F - 40hrs/week
    3717393 875 Greentree Rd
    Rep, Phlebotomy Services II, Tonawanda NY area, F/T 38hrs/wk, M-F 7:00a-2:30p, plus rot Sat 7a-12p
    3717399 2173 Sheridan Dr
    Rep, Phlebotomy Services - Norman, OK
    3717778 950 N. Porter
    Clinical Lab Supv - Hematology (nights) - Miramar, FL
    3717643 10200 Commerce Parkway
    Rep, Route Service I - TEMPORARY (Teterboro, NJ)
    3717798 One Malcolm Ave
    Rep, Phlebotomy Svcs I - CA
    3717746 450 Kings County Dr
    Floater, Phlebotomy Svcs - CA
    3717762 919 N Blackstone St
    Rep, Phlebotomy Svcs II - (P/T), Norton OH area, 20hrs/wk, M-F(9a-1p)
    3717528 2451 Edison Blvd
    Rep, Phlebotomy Svcs I - CA
    3717752 919 N Blackstone St
    Asst, Pre-Analytical I, NIGHTS - M-F 10pm-6:30am, plus rotating Saturdays
    3717391 875 Greentree Rd
    Route Service Rep - Part-Time 25 hrs/wk - M-F 10am-3pm
    3717518 592 Ellis Rd.
    Rep, Cust Svce - 9am-6pm Tampa
    3714858 3011 University Center Drive

older | 1 | .... | 33 | 34 | (Page 35) | 36 | 37 | .... | 119 | newer